
==== Front
Biomark Res
Biomark Res
Biomarker Research
2050-7771
BioMed Central London

644
10.1186/s40364-024-00644-3
Review
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao Yu 1
Yang Liang 1
Li Zhenning 2
Peng Xueqiang xqpeng@cmu.edu.cn

1
Li Hangyu sj_li_hangyu@sina.com

1
1 grid.412644.1 0000 0004 5909 0696 Department of General Surgery, The Fourth Affiliated Hospital, China Medical University, Shenyang, 110032 China
2 https://ror.org/032d4f246 grid.412449.e 0000 0000 9678 1884 Department of Oromaxillofacial-Head and Neck Surgery, School and Hospital of Stomatology, China Medical University, Liaoning Province Key Laboratory of Oral Disease, Shenyang, 110001 China
31 8 2024
31 8 2024
2024
12 934 6 2024
20 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Malignant tumors remain a primary cause of human mortality. Among the various treatment modalities for neoplasms, tumor vaccines have consistently shown efficacy and promising potential. These vaccines offer advantages such as specificity, safety, and tolerability, with mRNA vaccines representing promising platforms. By introducing exogenous mRNAs encoding antigens into somatic cells and subsequently synthesizing antigens through gene expression systems, mRNA vaccines can effectively induce immune responses. Katalin Karikó and Drew Weissman were awarded the 2023 Nobel Prize in Physiology or Medicine for their great contributions to mRNA vaccine research. Compared with traditional tumor vaccines, mRNA vaccines have several advantages, including rapid preparation, reduced contamination, nonintegrability, and high biodegradability. Tumor-targeted therapy is an innovative treatment modality that enables precise targeting of tumor cells, minimizes damage to normal tissues, is safe at high doses, and demonstrates great efficacy. Currently, targeted therapy has become an important treatment option for malignant tumors. The application of mRNA vaccines in tumor-targeted therapy is expanding, with numerous clinical trials underway. We systematically outline the targeted delivery mechanism of mRNA vaccines and the mechanism by which mRNA vaccines induce anti-tumor immune responses, describe the current research and clinical applications of mRNA vaccines in tumor-targeted therapy, and forecast the future development trends of mRNA vaccine application in tumor-targeted therapy.

Keywords

mRNA vaccines
Tumor-targeted therapy
Mechanism
Clinical application
Development trends
issue-copyright-statement© Yumed Inc. and BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Although there have been considerable advancements in cancer treatment, malignant tumors still remain a primary cause of human mortality [1]. Conventional modalities such as surgery, chemotherapy, and radiotherapy remain widely utilized. Additionally, immune checkpoint inhibitors (ICIs) have pioneered novel avenues in tumor-targeted therapy, showing efficacy across diverse malignancies [2]. The growing landscape of tumor-targeted therapy offers hope to cancer patients. This innovative modality enables precise tumor cell targeting, minimizes damage to normal tissues, is tolerable at high doses, and demonstrates significant therapeutic efficacy [3]. mRNA vaccines represent a novel technology at the intersection of molecular biology and immunology and is at the forefront of gene therapy (Table 1). In these vaccines, exogenous antigens encoded by mRNA are introduced into somatic cells, promoting the synthesis of antigenic proteins. This concurrent activation of the body’s principal immune mechanisms, namely, cellular and humoral immunity [4, 5], underscores the pivotal role of mRNA vaccines in tumor-targeted therapy. In recent decades, great strides in experimental techniques have catalysed the widespread utilization of mRNA vaccines across diverse domains, with an emphasis on tumor-targeted therapy. Currently, mRNA vaccines are used for the treatment of various diseases, yielding favourable outcomes [6–10]. (Fig. 1). This review comprehensively discusses the targeted delivery mechanisms of mRNA vaccines and their pivotal role in tumor-targeted therapy. It explores in detail the processes by which mRNA vaccines activate the immune system to recognize and attack tumor cells. Furthermore, this review explores the role of mRNA vaccines in modulating the tumor microenvironment, emphasizing their potential to enhance anti-tumor efficacy by optimizing the working conditions of immune cells. A thorough assessment of the research and application progress of mRNA vaccines in tumor-targeted therapy is presented, including numerous clinical trials that demonstrate their actual effectiveness and potential across multiple cancer types. Finally, this review anticipates future trends in this field, which are expected to further advance the development of mRNA vaccines in cancer treatment. Through this review, we aim to provide readers with a comprehensive and in-depth perspective that aids in understanding the central role of mRNA vaccines in cancer therapy and their promising future prospects. Table 1 Breakthroughs of mRNA vaccines in research

Year	Breakthrough in mRNA vaccine research	References	
1990	Concept proposal of mRNA vaccines	[11]	
1995	mRNA tested as cancer vaccine (in mice)	[12]	
2000	Exploration of mRNA as a novel vaccine approach	[13]	
2002	The first clinical trial with ex vivo DCs transfected with mRNA against cancer	[14]	
2006–2008	mRNA modifications to enhance stability and efficacy, leading to improved performance and longevity in vaccine applications and therapeutic interventions	[15–18]	
2010	Significant Progress of mRNA technology in infectious disease vaccines	[19]	
2012	Intranodal delivery of mRNA transfects DCs and elicits anti-tumor immunity	[20]	
2013	Debate on type I IFN in efficacy and safety of mRNA vaccines	[21]	
2020–2022	FDA approval of two mRNA vaccines of COVID-19	[22, 23]	
2022 to present	Research and clinical trials on personalized mRNA cancer vaccines	[24–26]	

Fig. 1 Application field of mRNA vaccines. Legend: The mRNA vaccine delivery systems primarily encompass three categories: 1) Carrier-based delivery systems, including lipid nanoparticles (LNPs), cationic nanoemulsions (CNEs), cationic peptides (e.g., protamine), viral replicating particles (VRPs), and polymers. 2) Dendritic cell mRNA delivery systems (DCs mRNA). 3) Naked mRNA. Presently, mRNA vaccines are predominantly employed in the treatment of various diseases, such as: 1) Cardiovascular diseases, including myocardial infarction and heart failure [6]. 2) Metabolic diseases, such as muscular dystrophy [7] and porphyria [8]. 3) Genetic disorders, including glycogen storage disease [9]. 4) Allergic diseases, such as food allergies [27]. 5) Infectious diseases, including human papillomavirus (HPV) [28], Corona Virus Disease 2019 (COVID-19) [29], and human immunodeficiency virus (HIV) [30], among others. 6) Tumors, such as prostate cancer [10] and glioma [31], among others. Naked mRNA vaccines are primarily utilized in the treatment of tumors [32] and infectious diseases [33]. DC-loaded mRNA vaccines are mainly applied in the treatment of tumors [10]

Overview of mRNA vaccines: principle, classification, synthesis and biomarkers

mRNA vaccines are based on the "central dogma" of molecular biology and involve the optimization, chemical modification, and purification of mRNAs with specific antigens [34]. There are two main types of mRNA vaccines: self-amplifying (SAM) and nonreplicating vaccines [35]. SAM vaccines alter a virus's genome to include mRNAs encoding antigens, allowing self-replication without viral protein synthesis and increasing safety and efficiency. Nonreplicating vaccines contain only full-length mRNAs encoding the antigen, with a 5' cap structure and 3' poly(A) tail. Despite their simple structure and direct antigen focus, they have the drawbacks of a short half-life and low in vivo antigen expression [36], necessitating higher doses for effectiveness. The generation of designed DNA templates into an RNA strand is guided by the principle of base complementarity [37]. This process is accomplished through in vitro transcription (IVT), which involves sequence construction, IVT, capping, and tailing, is the primary method for synthesizing mRNA vaccines [38]. DNA templates for IVT must have an open reading frame (ORF), a 5' UTR and 3' UTR, and for self-amplification, a long ORF. The ORF contains start and stop codons [39], allowing splicing for mature mRNA production. The 5' UTR and 3' UTR regulate mRNA stability and translation [40]. The primary challenge facing IVT mRNAs is their immunogenicity. To address this issue, modifications using nucleotides can increase RNA stability and minimize immunogenicity. Among various nucleotide modification methods, chemical alterations, poly(A) tail addition, and sequence optimization are commonly employed [15]. Furthermore, mRNA purification is crucial for eliminating immunogenic properties [41]. Purification techniques mainly include different chromatographic methods (e.g., high-performance liquid chromatography (HPLC) [42], ion exchange [43], size exclusion [44], affinity [45], and Fast protein liquid chromatography (FPLC) [46]), adsorption [47], and membrane technology [41]. The cap structure shields mRNA from exonuclease degradation, ensuring mRNA stability and enhancing translation efficiency [48]. Methylation can be utilized to cap mRNAs in three primary forms: Cap0, Cap1, and Cap2. Traditional enzymatic capping is achieved by enzymatic capping [49], which involves RNA 5'-triphosphatase (RTPase) hydrolysing the 5′ end of RNA, which transfers guanosine monophosphate (GMP) via guanylyltransferase (GTase) to form a cap structure (m7GpppNp), which can be further modified to cap1 (m7GpppN1mp) or cap2 through 2'-O-methyltransferase. Cotranscriptional capping with a Cap analogue (m7GpppG) is also a common method [50] used during mRNA transcription [51]. However, studies have indicated that capping analogues may disrupt mRNA binding, affecting translation efficiency by hindering ribosome recognition and proper 5' end determination [52, 53]. Adding a poly(A) tail is essential for ensuring the stability of mRNA after transcription [54]. There are two main methods used for adding poly(A) tails to mRNAs. The first involves traditional enzymatic polyadenylation, in which the poly(A) tail is added to the 3' end of the mRNA without changing the length of the tail [55]. The other method involves obtaining a poly(A) tail of controllable length by formatting a fixed-length poly(A) sequence on the basis of a DNA template and transcribing it [56]. The ideal length of the poly(A) tail falls within the range of 120 to 150 nucleotides [57–59]. Research on biomarkers for mRNA vaccines remains limited, encompassing two primary areas: 1) Immunophenotyping. Studies have indicated that immunophenotyping can reflect the expression levels of immune checkpoint (ICP) and immunogenic cell death (ICD) regulators, suggesting its potential as a therapeutic biomarker for mRNA vaccines [60]. 2) Tumor antigens. Lin et al. identified six genes that may serve as vaccine targets and stimulate antigen-presenting cell (APC) activation in glioblastoma (GBM), suggesting that these genes are potential biomarkers for mRNA vaccines [61]. Another study demonstrated that patients with malignant mesothelioma (MESO) characterized by high expression of the oncogene fibronectin 1 (FN1) may develop resistance to mRNA vaccination. Consequently, the authors suggest that FN1 could serve as a potential biomarker for mRNA vaccines [62]. However, these studies are primarily bioinformatics analyses, and further exploration through in vitro and in vivo studies is necessary to elucidate the biomarkers associated with mRNA vaccines.

Targeted delivery mechanism of mRNA vaccines

A reliable and secure targeted delivery mechanism is highly important for the progress of mRNA vaccine technology [63]. Currently, several mRNA delivery systems are known, including, Carrier based delivery system, naked mRNA and the dendritic cell-mRNA delivery system (DCs-mRNA) [64](Table 2). Table 2 mRNA vaccine delivery systems

Delivery types	Delivery subtypes	Advanntages	Challenges	
Carrier based delivery system	Liposomes and their derivatives, mainly lipid nanoparticles(LNPs) [65]	Lipid nanoparticles (LNPs) demonstrate a remarkable mRNA encapsulation efficiency, which is pivotal for the protection of mRNA from nuclease degradation and subsequent stable delivery to the target cells

Moreover, LNPs possess a distinct advantage in terms of tissue penetration, which facilitates deeper penetration into tissues and organs, thereby enabling more widespread and efficient cellular uptake. The nanoscale dimensions of LNPs contribute to their enhanced intracellular delivery, as they can easily traverse cellular barriers and accumulate within the target cells

In addition to their delivery efficiency, LNPs exhibit low cytotoxicity and immunogenicity, which are critical attributes for their application in therapeutic settings

Another notable feature of LNPs is their potent adjuvant properties, which are essential for enhancing the immune response when delivering vaccines or immunotherapies [66–68].

	Lipid nanoparticles (LNPs) are susceptible to degradation, showcasing suboptimal stability under storage conditions, with a propensity for aggregation and fusion phenomena, which can compromise their structural integrity and therapeutic efficacy [69].	
Polymers [70]	Certain polymers have demonstrated the ability to significantly enhance the process of endosomal escape, thereby improving the delivery efficiency of therapeutic agents. Additionally, these polymers provide protection for messenger RNAs (mRNAs) against enzymatic degradation, ensuring their stability, and facilitate a safe and effective release of mRNAs into the cytoplasm for subsequent translation [71].	The low purity and high molecular weight of polymer-based delivery vectors, coupled with their high charge density, can result in significant cytotoxicity [72]	
Virus-like replicon particles [73]	Viral replicon particles (VRPs) have the unique capacity to encapsulate self-amplifying RNA (saRNA)-encoded antigens, effectively facilitating their transport to the cytosol. Through in vitro synthesis, viral structural proteins can be produced and utilized for encapsulating saRNAs that encode specific antigens. Extensive researches [74] has illuminated the therapeutic potential of mRNA vaccines administered via VRPs across a diverse array of viral, bacterial diseases, and cancer. This method enhances RNA replication, elicits potent innate immune responses, and promotes the maturation of dendritic cells, contributing to the vaccines' efficacy and immunogenicity.	Viral replicon particles (VRPs) possess a notable disadvantage, as they have been observed to elicit neutralizing antibody responses specifically targeted against the viral surface proteins, as evidenced by studies [75, 76].	
Cationic nanoemulsion (CNE) [77]	CNE can enhance the efficacy of mRNA vaccines by binding to saRNA in a pH-dependent manner, comprising nanoemulsions and cationic lipids. Nanoemulsions can be generated via techniques such as ultrasound, microfluidics, and vigorous stirring [78]. Among the CNE components, the cationic lipid 1.2-diol sn glycerol-3-phosphate choline (DOTAP) stands out for its positive charge, being emulsified with MF59, the identical adjuvant component of the lotion [79]. Additionally, CNE has shown promising therapeutic effects in its ability to deliver saRNA, indicating that lower doses of adjuvant subunits in CNE complexes can elicit substantial immune responses [80]. Numerous studies have been conducted to investigate the stability, toxicity, and biodistribution of CNE, with findings confirming its stability [81].	However, the conclusions regarding the toxicity of CNE vary across different models. One study demonstrated that the toxicity of nanoemulsions on human foetal lung cells (MRC-5) is dose-dependent [82]. In contrast, another investigation revealed that the rabies animal model exhibited suitable tolerance to CNE-delivered self-amplifying mRNA (SAM) vaccines [83]	
Cationic cell-penetrating peptides (CPP) [84, 85]	Cationic peptides, including protamine, a well-established cationic peptide utilized for mRNA transport [86], facilitate the formation of nanosized complexes with mRNAs. These complexes effectively shield the mRNA from enzymatic degradation, maintain immunogenicity across varying temperatures, and preserve the potency of antigen-encoded mRNA vaccines [87]. Protamine's ability to spontaneously condense mRNA via electrostatic interactions serves to protect the enclosed mRNA from degradation by extracellular RNases [88, 89]. Furthermore, the protamine-mRNA complexes demonstrate adjuvant properties, stimulating TLR7/8 to trigger robust innate immune responses [90].	The specific combination ratio and binding strength between protamine and mRNA are crucial factors that can significantly influence the translation process. These parameters may impose limitations on the efficiency of vaccine protein expression, ultimately affecting the overall effectiveness of the vaccine in eliciting an immune response and providing protection [91].	
Naked mRNA	-	First, the mRNA cannot be integrated into the genome, reducing the risk of genetic mutations. Second, ribosomes can bind directly to the mRNA in the cytoplasm, causing the mRNA to be translated immediately and rapidly initiating an immune response after vaccination. Third, the final position of the mRNA determines the site of protein expression, allowing for precise control of protein expression [92, 93].	The lack of a carrier during the delivery process can lead to unstable protein translation and expression. However, this can be mitigated by altering the administration method and proper chemical modifications. However, research in this area is relatively limited at present [94].	
Dendritic Cell-mRNA Delivery System (DCs-mRNA)	-	Dendritic cells (DCs) serve as the orchestrators of the immune response, exhibiting unparalleled efficiency in their ability to capture and present antigens. This is achieved through a meticulously regulated process involving internalization and proteolytic degradation. Following this intricate mechanism, DCs proceed to present antigens to CD8 + T or CD4 + T cells via major histocompatibility complexes (MHCs), specifically MHC class I (MHCI) or MHC class II (MHCII). By doing so, they initiate an adaptive immune response [95]. The pivotal role of DCs in this context underscores their significance as prime targets for vaccination strategies.	Challenges primarily include the two aspects: Firstly, serum protein aggregation and mRNA degradation upon systemic administration [96], compromising vaccine integrity. Additionally, the second challenge involves the efficient systematic dissemination of mRNA vaccines, ensuring uniform distribution [97] for optimal immune response.	

Carrier based delivery system

Two major types of carrier molecules have been utilized in nucleotide delivery systems: viral carriers and non-viral carriers [98]. However, owing to associated limitations such as potential immunogenicity, tumorigenicity, and low drug loading, the use of viral carriers has been limited. Conversely, nonviral carriers, including liposomes and their derivatives [65], polymers [70], virus-like replicon particles [73], cationic nanoemulsion (CNE) [77], and cationic cell-penetrating peptides (CPP) [84, 85], have garnered significant attention. Among these carriers, liposomes and their derivatives, particularly lipid nanoparticles (LNPs) [99, 100], stand out as widely employed delivery systems. LNPs typically have four key components: ionizable amino lipids, cholesterol, polyethylene glycol lipids, and auxiliary lipids such as double stearyl phosphatidylcholine (DSPC) [101–103]. LNPs, which are approximately 100 nm in diameter, are strikingly similar in both size and composition to various viral entities, mirroring the dimensions of infectious agents such as the SARS-CoV-2 virus (approximately 100 nm), influenza A virus (ranging from 80 to 120 nm), and mature HIV particles (approximately 100 nm in diameter) [104]. Post-administration, LNPs are dynamically transported to cells expressing lipid or scavenger receptors akin to natural apolipoprotein conveyance. LNPs offer notable advantages, including high delivery efficacy [105] and commendable biocompatibility. Polymer materials primarily feature cationic liposome polymers (LPPs) with a positive charge that are proficient in mRNA encapsulation to enable protein expression while mitigating degradation risks. However, these methods have limitations such as polydispersity and macromolecule elimination [106]. Lipid nanoparticles (LNPs) exhibit high mRNA encapsulation efficiency and effective cellular transfection, coupled with robust tissue penetration, low cytotoxicity and immunogenicity, and potent adjuvant properties [66–68]. However, LNPs are prone to degradation and exhibit relatively poor stability during storage, tending to aggregate and fuse [69]. Nevertheless, numerous preclinical and clinical trials have confirmed that LNPs hold promising potential as mRNA vaccine carriers, capable of effectively activating immune responses. Continuous technological advancements have led to LNPs with more complex structures and enhanced physical stability [107], yielding substantial achievements in the innovation of vaccine delivery systems [71]. LPPs encompass diverse materials like polyethyleneimine (PEI) [108], polyamide amine (PAMAM) dendritic polymer [109], dendritic macromolecular polypropylene imine [pol (propylene imine), PPI], polyurethane [poly (aminoester), PAE], and polysaccharides [110]. Polyethylenimine (PEI) has been shown to enhance endosomal escape, protect mRNAs from degradation, and facilitate safe release into the cytoplasm [111]. However, the low purity and high molecular weight of polymer-based delivery vectors, coupled with their high charge density, can result in significant cytotoxicity [72]. Cationic peptides, characterized by cations or amphiphilic amino groups (e.g., arginine) in the main and side chains, facilitate mRNA delivery. Notably, protamine, a renowned cationic peptide for mRNA transport [86], forms nanosized complexes with mRNAs to safeguard against RNA enzyme degradation and stabilize immunogenicity across temperatures while preserving the efficacy of antigen-encoded mRNA vaccines [87]. Protamine can spontaneously condense mRNA through electrostatic interactions, thereby protecting the encapsulated mRNA from degradation by extracellular RNases [88, 89]. Additionally, protamine-mRNA complexes can function as adjuvants, activating TLR7/8 to elicit innate immune responses [90]. The combination ratio and binding strength between protamine and mRNA can have implications for the translation process, potentially limiting vaccine protein expression efficiency and overall vaccine effectiveness [91]. Viral replicon particles (VRPs) have the capacity to encapsulate self-amplifying RNA (saRNA)-encoded antigens and facilitate their transportation to the cytosol. In vitro synthesis of viral structural proteins allows for their encapsulation as saRNAs encoding specific antigens. Numerous studies have highlighted the therapeutic potential of mRNA vaccines delivered via VRPs against a spectrum of viral diseases, bacterial diseases, and cancer [74]. It enhances RNA replication, triggers innate immune responses, and promotes the maturation of dendritic cells. However, it also has the drawback of inducing neutralizing antibody responses against the viral surface [75, 76]. CNE can enhance the efficacy of mRNA vaccines by binding to saRNA in a pH-dependent manner, comprising nanoemulsions and cationic lipids. Nanoemulsions can be generated via techniques such as ultrasound, microfluidics, and vigorous stirring [78]. Notably, among the CNE components, the cationic lipid 1.2-diol sn glycerol-3-phosphate choline (DOTAP) stands out for its positive charge, being emulsified with MF59, the identical adjuvant component of the lotion [79]. Additionally, a preclinical study conducted by Brito et al. on the ability of CNE saRNA delivery in rabbits, mice, and nonhuman primates revealed promising therapeutic effects of CNE and indicated that lower doses of adjuvant subunits in CNE complexes could elicit substantial immune responses [80]. Numerous studies have been conducted to investigate the stability, toxicity, and biodistribution of CNE, with findings confirming its stability [81]. However, the conclusions regarding its toxicity vary across different models. One study demonstrated that the toxicity of nanoemulsions on human foetal lung cells (MRC-5) is dose-dependent [82]. In contrast, another investigation revealed that the rabies animal model exhibited suitable tolerance to CNE-delivered self-amplifying mRNA (SAM) vaccines [83]. Biomimetic carriers represent an innovative drug delivery concept employing endogenous substances, biological structures, and processes. Exosomes, a type of lipid bilayer microvesicle characterized by small size and low immunogenicity, are a particularly auspicious biomimetic carrier. Exosomes can prolong the duration of drugs in circulation by evading mononuclear phagocytic system clearance, thereby increasing drug delivery efficiency [112]. In addition, promising new materials for mRNA vaccine delivery research, such as inorganic nanomaterials and hydrogels, are also being explored. Compared with traditional materials, these new materials have great advantages in terms of improving the efficiency and intensity of vaccine mRNA translation [113].

Naked mRNA

Naked mRNA delivery refers to the direct administration of mRNA. This technology has been successfully used in vivo for immune responses, specifically targeting antigen-presenting cells through intradermal [92, 114] and intranodular injections [115, 116]. There are many advantages associated with this delivery method [92, 93]. First, the mRNA cannot be integrated into the genome, reducing the risk of genetic mutations. Second, ribosomes can bind directly to the mRNA in the cytoplasm, causing the mRNA to be translated immediately and rapidly initiating an immune response after vaccination. Third, the final position of the mRNA determines the site of protein expression, allowing for precise control of protein expression. Despite its advantages, naked mRNA delivery also has some major drawbacks [94]. The lack of a carrier during the delivery process can lead to unstable protein translation and expression. However, this can be mitigated by altering the administration method and proper chemical modifications. However, research in this area is relatively limited at present.

Dendritic Cell-mRNA Delivery System (DCs-mRNA)

DCs are the orchestrators of the immune response, showing unparalleled efficiency in capturing and presenting antigens through a meticulously regulated process of internalization and proteolytic degradation. Subsequently, DCs present antigens to CD8 + T or CD4 + T cells through major histocompatibility complexes (MHCs), specifically MHCI or MHCII, thereby initiating an adaptive immune response [95]. This highlights DCs as prime targets for vaccination. Typically, specific mRNAs encoding antigens are delivered into DCs via electroporation, lipid transfection, nuclear transfection, or in vitro acoustic evaporation. Among these techniques, electroporation is preferred [24]due to its high transfection efficacy and independence from carrier molecules. Challenges primarily include the following two aspects: Firstly, serum protein aggregation and mRNA degradation upon systemic administration. Experts suggest addressing this issue by supplementing DCs with granulocyte–macrophage colony-stimulating factor (GMCSF) and IL-4 [96]. The second challenge lies in the systematic dissemination of mRNA vaccines [97].

Mechanism of mRNA Vaccine-Induced anti- tumor immune response

The mechanisms by which mRNA vaccines induce an anti-tumor immune response involve two primary mechanisms. First, they directly induce tumor-specific T-cell responses, including both innate and adaptive immune responses. During this process, mRNA vaccines deliver tumor-associated antigens or tumor-specific antigens generated by intratumoral mutations to the immune system, activating antigen-presenting cells (APCs) and T cells and thereby initiating a specific antitumor immune response. Second, they achieve induction of an antitumor immune response by modulating the tumor microenvironment.

Key factors in the induction of anti- tumor immune response by mRNA vaccines

The key factors in the mRNA vaccine-induced antitumor immune response include the following aspects. First, the design of the vaccine is crucial [117]. By precisely selecting tumor-associated antigens, a vaccine can ensure high specificity and effectiveness. Second, efficient antigen presentation is a key step in inducing an anti-tumor immune response [118]. mRNA vaccines express tumor-associated antigens, making them targets antigen-presenting cells (APCs) in vivo and thereby enhancing antigen presentation efficiency [119]. Third, a refined immune regulatory mechanism contributes to achieving immune balance [120]. mRNA vaccines can induce the generation of immunosuppressive cells and inflammatory factors to balance the immune response, preventing excessive immune damage [121].

Molecular mechanisms underlying the activation of anti- tumor immune response by mRNA vaccines

The molecular mechanisms underlying mRNA vaccine-induced activation of anti-tumor immune responses involve multiple factors, including antigen presentation, immune cell activation, immune regulation, and antigen stimulation of B cells [122].

Inducing innate immunity

Congenital immune stimulation is driven primarily by the response mechanism of immune cells in defence against pathogens. The Golgi apparatus and endoplasmic reticulum cooperate to translate protein fragments via the MHC [123]. Following DC activation, the MHC can identify corresponding T cells and initiate cytotoxic lymphocyte immunity [124]. MHC complexes and TCRs found on the surface of T cells are the first signals that trigger cellular immune responses. Several components of mRNA vaccines can interact with pattern recognition receptors (PRRs) in endosomes, including TLR3/7/8, which can detect pathogen-associated molecular patterns (PAMPs) in mRNAs. TLR7/8 recognizes single-stranded RNA (ssRNA), whereas TLR3 detects double-stranded RNA (dsRNA). APCs can identify mRNAs and activate TLRs [125]. The activated TLR detects PAMPs and triggers the second signal. The activated second messenger translocates to the nucleus and functions as a potential transcription factor. It can recruit various transactivating factors to promote the expression of proinflammatory cytokines and chemokines such as interleukin-6(IL-6), interleukin-2(IL-2), and tumor necrosis factor-α (TNF-α), thereby activating naive T cells via dual signalling pathways. However, there may be insufficient T lymphocytes to initiate cellular immune responses. Therefore, when these stored cells are exposed to the same antigen again, they are quickly activated. The proper absorption of APCs is a prerequisite for the activation of an immune response, with DCs being primarily responsible. A previous study [126] showed that mRNA vaccines have the ability to stimulate DC cell maturation. In non-immune cells, RIG/MDA5 recognize exogenous mRNA, activating cytokine and chemokine production [127]. Subsequently, they are able to recruit innate immune cells (Fig. 2).Fig. 2 mRNA vaccine induces innate immune mechanism. Legend: Upon stimulation of DC cells, the T cells undergo identification, whereby the MHC complex and TCR receptor on their surface serve as the initial signals for cellular immune response. Antigen-presenting cells (APCs) recognize the mRNA, activating TLR and prompting the detection of PAMP, thereby initiating the second signal. The activated second signal translocates to the nucleus as a transcription factor, recruiting various Trans-acting factors to facilitate the expression of proinflammatory cytokines and chemokines. This dual signal pathway effectively activates the initial T cells. In non-immune cells, RIG-I and MDA5 are involved in sensing exogenous mRNA and inducing cytokines/chemokines to recruit innate immune cells

Inducing adaptive immunity

After translation, APCs, such as DCs, take up the protein encoded by mRNA by a variety of mechanisms including micropinocytosis, endocytosis, or phagocytosis [128]. Antigens can be transiently expressed and accumulate in the cytoplasm, allowing for rapid processing into peptides that can be recognized by MHC I. Ribosomal translation generates various antigenic proteins, which are then degraded into fragments in proteasomes and presented as CD8 + T-cell epitopes by MHC-I. Alternatively, antigens can also be transported directly from the cytoplasm to lysosomes, or lysosomal-targeting sequence antigen proteins can be incorporated into mRNA structural design, followed by lysosomal disintegration and presentation as CD4 + T-cell epitopes by MHC-II. In summary, APCs can present exogenous antigens to CD4 + T cells through MHC-II while also cross-presenting exogenous antigens to CD8 + T cells via MHC-I, resulting in the activation of cytotoxic T cells. This stimulation method is termed cross-stimulation. CD4 + T cells can provide support to other immune cells, including B cells and CD8 + T cells, through their helper functions. Ultimately, the cloning amplification of alloantigen-specific T and B cells can result in the elimination of target cells. Furthermore, all nucleated cells possess the ability to process mRNA and present various translated proteins as well as peptides in the MHC-I pathway. Among them, only APCs can present on both MHC-I and MHC-II, triggering immunological responses from CD4 + T or B cells. However, prior to activating adaptive immunity, understanding how cells recognize non-self mRNAs and activate signaling cascades through the interplay of mRNAs, PRRs, and PAMPs is critical. PRRs that can perceive these PAMPs are mainly categorized into two distinct types: extracellular and intracellular [129]. PRRs that recognize RNA contribute to the production of IFN-I. Furthermore, IFN-γ can stimulate the activation of Protein Kinase R (PKR) and eIF2α phosphorylation, leading to cellular and humoral immune responses. As a result, IFN-γ is expected to provide immunological protection to the body. However, mRNA vaccines can overstimulate the immune response, causing excited cells to generate a significant amount of IFN-I, which inhibits mRNA translation and promotes mRNA degradation. Consequently, this downregulates the expression of the target protein, causing a negative reaction on the immune response. Therefore, an effective mRNA vaccine should completely activate innate immunity before initiating adaptive immunity (Fig. 3).Fig. 3 mRNA vaccine induces adaptive immune mechanism. Legend. After translation, the proteins encoded by mRNA are taken up by antigen-presenting cells (APCs) via mechanisms such as micropinocytosis, endocytosis, or phagocytosis. These antigens are subsequently processed into peptides and loaded onto the MHC class I pathway. The translation conducted by ribosomes produces immunogenic proteins, which are degraded into fragments within the proteasome and presented to CD8 + T cells via MHC-I. An alternative pathway allows for the direct transport of antigens from the cytoplasm to lysosomes, or the incorporation of a lysosome-targeting sequence within the mRNA structure for lysosomal degradation. The resulting MHC-II peptide complexes are then recognized by the T cell receptor (TCR) on CD4 + T cells

Modulation of the tumor microenvironment by mRNA vaccines

Based on definition provided in a previous report [130], the tumor microenvironment can be described as a local inner environment composed of tumor-infiltrating immune cells, interstitial cells, and active mediators released by these cells along with tumor cells. This microenvironment is critical for tumor growth and progression because it provides important nutrients and energy while also assisting tumor cells in evading immune system responses. Furthermore, the tumor microenvironment has been shown to increase the propensity of tumors to metastasize to other parts of the body. mRNA vaccines, as novel strategies for cancer immunotherapy, also greatly affect the tumor microenvironment [131].

The role of tumor microenvironment during tumor progression

The tumor microenvironment is a complex and dynamic ecosystem within tumor tissue that consists of a diverse array of components, such as tumor cells, immune cells, fibroblasts, extracellular matrix proteins, and an intricate network of cytokines and chemokines. These elements interact in a highly regulated manner, playing crucial roles in tumor growth, invasion, immune evasion, and response to therapy. Understanding the interactions within the tumor microenvironment is essential for developing effective strategies for cancer treatment and improving patient outcomes [132]. For example, cancer-associated fibroblasts (CAFs) and other immune cells have been reported to contribute to this process [133].The tumor microenvironment provides a favorable habitat in which the tumor cells can rapidly proliferate, evade immune surveillance, and metastasize [134]. Tumor cells adapt and evade the immune system by modulating immune suppression signals in response to antitumor immunological pressure [135]. Ultimately, tumor cells create an immunosuppressive microenvironment, which can enhance anti-tumor immunity and promote tumor survival. Thus, an ideal mRNA vaccine may alter the composition of local immune cells while restoring tumor immune surveillance.

mRNA vaccines can alter the distribution of cytokines in the tumor microenvironment

First, mRNA vaccines can alter the levels of cytokines in the tumor microenvironment by expressing tumor-associated antigens, thereby influencing the activation of immune cells and inflammatory responses [136]. The expression of tumor-associated antigens activates immune cells, particularly CD4 + T cells and CD8 + T cells, prompting them to release more cytokines [137]. An increase in these cytokines can disrupt the balance between immunosuppressive cells and inflammatory factors in the TME, making it easier for immune cells to penetrate into tumor tissues and eliminate tumor cells [138]. mRNA vaccines can promote DC maturation through TLR signaling. mRNA vaccines activate the transcription factor NF-κB via the MyD88 and TRIF pathway, thus promoting the generation of cytokines such as interleukins(ILs), tumor necrosis factors(TNFs), and interferon(IFNs), as well as the maturation of cytotoxic T lymphocytes (CTLs), resulting in the elimination of solid tumors during tumor targeted therapy [139]. Furthermore, mRNA vaccines can promote cytokine release by helper T cells, thereby increasing the level of antibodies of the humoral dependent immunity [140]. Furthermore, mRNA vaccines can enhance the recruitment and activation of antigen-presenting cells (APCs) in the TME [141]. APCs, like dendritic cells, macrophages, and B cells, initiate immune responses by presenting tumor antigens to T cells through mRNA vaccines, activating specific anti-tumor immunity [142]. This process helps to establish a bridge between innate and adaptive immune responses in the TME, thereby enhancing anti-tumor immune activity. In addition, mRNA vaccines can also regulate the expression of immune checkpoint molecules in the TME [143]. Immune checkpoints are a type of immune inhibitory molecules that play a key role in regulating immune responses and maintaining self-tolerance [144]. mRNA vaccines can influence the expression of immune checkpoint molecules on immune cells and tumor cells, potentially overcoming the immune evasion mechanisms employed by tumors [28]. By intervening in immune checkpoints, mRNA vaccines can enhance anti-tumor immune responses and improve the efficacy of tumor immune therapy [119].

mRNA vaccines can modulate tumor immune microenvironment (TIME)

mRNA vaccines have the potential to reshape the tumor immune microenvironment (TIME) via two primary mechanisms: 1) regulating the balance between M1 and M2 macrophages and 2) stimulating cytokine release by different types of T cells (Fig. 4). The interaction of malignant cells and immunological components in the tumor microenvironment (TME) has a great effect on tumor growth and maturation. Tumor cells frequently exploit immunosuppressive mechanisms, such as the production of immunosuppressive proteins, to evade immune surveillance. However, studies have shown that mRNA vaccines can restore tumor immunosurveillance by increasing MHC-I expression [145]. mRNA vaccines can also inhibit tumor growth by regulating the ratio of M1 to M2 macrophages to control tumor progression. Macrophages carry out their functions through two subtypes: M1 and M2. M1 macrophages promote inflammation, whereas M2 macrophages suppress it. In the tumor microenvironment, macrophages mostly exhibit the M2 phenotype. However, studies have shown that mRNA vaccines can increase the ratio of M1 macrophages to M2 macrophages by promoting the transformation of M2 macrophages into M1 macrophages. This is particularly useful for suppressing tumor growth and mitigating tumor immune escape [146].Fig. 4 mRNA vaccines reshape tumor immune microenvironment (TIME). Legend.mRNAvaccine possesses the potential to reshape the tumor immune microenvironment via two primary mechanisms. Firstly, it regulates the equilibrium between M1 and M2 macrophages, thus transforming M2 macrophages into M1 macrophages. Secondly, it induces the secretion of cytokines by various T cells (For example T helper cell). Additionally, the vaccine promotes the maturation of dendritic cells (DC) through Toll-like receptor (TLR) receptors, activates the transcription factor NF kB to stimulate the maturation of cytotoxic T lymphocytes (CTL), and prompts T helper cells to secrete cytokines

Research and current applications of mRNA vaccines in tumor targeted therapy

In the realm of tumor-targeted therapy, mRNA vaccines are utilized in two main ways: mRNA tumor vaccines directly target tumor cells, and increasing treatment effectiveness by combining mRNA vaccines with other tumor-targeted therapies, such as immune checkpoint inhibitors. The continual evolution of these strategies has revolutionized tumor-targeted therapy, presenting novel avenues to enhance treatment outcomes among cancer patients and illustrating the promising role of mRNA vaccines in combating cancer.

mRNA tumor vaccines

Currently, mRNA tumor vaccines produced using IVT mainly target four distinct types of molecules: (1) encoding tumor-associated antigens (TAA), (2) encoding tumor-specific antigens (TSA), (3) encoding tumor-Associated Viruses.

mRNA vaccines encoding TAAs

TAAs are expressed in normal cells as well, but at relatively higher levels in tumor cells [147]. These antigens typically arise from abnormal differentiation or dysfunction of tumor cells, such as carcinoembryonic antigen (CEA), PRAME, NY-ESO-1, etc. [148–150]. Although TAAs are expressed to some extent in normal tissues, the significant upregulation of their expression in tumor cells allows the immune system to generate targeted immune responses [151]. The utilization of TAAs as targets for mRNA vaccines has already initiated clinical investigations in various solid tumors and haematologic malignancies. mRNA vaccines have the potential to be designed for TAAs that are selectively expressed in cancer cells. CA125 is a TAA in ovarian epithelial carcinoma, whereas AFP is a TAA in liver cancer. Several clinical trials have used mRNA vaccines targeting similar TAAs for therapy, including NCT00831467, NCT03164772, and NCT01995708 [24]. (Table 3). Table 3 Clinical trials of mRNA vaccines encoding TAAs

Cancer type	NCT number	Drug administration	Phase	TAA type	Status	Delivery system	Result	
Respiratory system tumors (mainly non-small cell lung cancer)	non-small cell lung cancer	NCT03164772	BI 1361849 (CV9202) + Durvalumab + / − Tremelimumab	I/II	EGFR	Recruiting	Protamine	Good tolerance, and most patients (84%) have found antigen specific immune responses [24]	
NCT00923312	mRNACV9201	I/II	EGFR	Recruiting	Protamine	Good tolerance and immune response detected after treatment; The median progression and overall survival time were 5 months and 10.8 months, respectively [86]	
NCT01915524	With local irradiation (with or without pemetrexed and with or without EGFR tyrosine-kinase inhibitor)	I	EGFR	Recruiting	Naked RNA	Detectableantigen-specificimmunity in 21 (84%) patients. One (4%) patient had partial response in combination with chemotherapy treatment, and 12 (46%) patients had stable disease [25]	
Reproductive system tumors	ovarian cancer	NCT04163094	W_ova1 + carboplatin/paclitaxel	I	OVA-1	Recruiting	Naked RNA	Not published	
recurrent epithelialOC	NCT01334047	DC-006 vaccine (mRNA encoding hTERT, survivin)	I/II	hTERT	Recruiting	DC	Not published	
Penile Neoplasms Malignant	NCT03418480	BNT113 (HPV16 E6 and E7 oncoproteins)	I/II	E6/E7	Recruiting	Unkown	Not published	
ovarian cancer	NCT01456065	DCs loaded with TERT-mRNA and Survivin-peptide	I	TERT-mRNA and Survivin-peptide	Unknown	DC	Not published	
Skin tumor (mainly melanoma)	melanoma	NCT02410 733	NY-ESO-1, tyrosinase, MAGE-A3, and TPTE	I	NY-ESO-1, MAGE-A3, tyrosinase, TPTE	Active, not publishedt recruiting	Lipid nanoparticles	Immune responses against a minimum of one tumourassociated antigen in 39 (75%) patients. mRNA vaccine with anti-PD-1 therapy: six (35%) patients had partial response and two (12%) had stable disease; mRNA vaccine monot publishedtherapy: three (12%) patients had partial response, and seven (28%) had stable disease [152]	
NCT04526899	BNT111 (NY-ESO-1, tyrosinase, MAGE-A3, and TPTE) + cemiplimab	II	NY-ESO-1, MAGE-A3, tyrosinase, TPTE	Recruiting	RNA-LPX	Good tolerance, strong CD4 + and CD8 + T cell immunity after treatment, combined with PD-1 inhibitors, achieving an objective response rate of 35% [153]	
NCT00940004	Dendritic cells electroporated with mRNA encoding gp100 and tyrosinase	I/II	gp100	Completed	DC	Not published	
NCT01676779	mRNA; b.TAAs: MAGE-A3, MAGE-C2, tyrosinase, gp100	II	NY-ESO-1, MAGE-A3, tyrosinase, TPTE	Completed	DC	Good tolerance (symptoms: transient local skin reactions, flu like symptoms, shivering after infusion), and may increase the one-year survival rate (71% in the treatment group, 35% in the control group) [154]	
NCT01302496	mRNA; b.TAAs: MAGE-A3, MAGE-C2, tyrosinase, gp100	II	NY-ESO-1, MAGE-A3. tyrosinase. TPTE	Completed	DC	12 out of 15 patients showed T cell stimulation response.Some patients have strong immune responses; Both single therapy and combination therapy can induce multifunctional CD8 + T cell responses, which may provide a benchmark for achieving the immune stimulation levels required for sustained clinical remission [26]	
NCT01676779	mRNA; TAAs: MAGE-A3, MAGE-C2, tyrosinase, gp100	II	mRNA; TAAs: MAGE-A3, MAGE-C2, tyrosinase, gp100	Completed	DC	Good tolerance (symptoms: transient local skin reactions, flu like symptoms, shivering after infusion), and may increase the one-year survival rate (71% in the treatment group, 35% in the control group)	
NCT01456104	Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)	I	HLA-A	Completed	DC	Unknown	
NCT00978913	DCs transfected with hTERT, survivin and p53	I	hTERT, survivin and p53	Completed	DC	Unknown	
NCT00961844	Dendritic cells—transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion + Temozolomid	I/II	hTERT-, survivin- and tumor cell derived mRNA	Terminated	DC	Unknown	
NCT00929019	Autologous dendritic cells electroporated with mRNA	I/II	HLA-A2	Terminated	DC	Not reported	
NCT01302496	mRNA; b.TAAs: MAGE-A3, MAGE-C2, tyrosinase, gp100s	II	MAGE-A3, MAGE-C2, tyrosinase, gp100s	Completed	DC	Among the 15 patients, 12 had T cell stimulation response; Some patients have strong immune responses; Both single therapy and combination therapy can induce multifunctional CD8 + T cell responses, which may provide a benchmark for achieving immune stimulation levels required for sustained clinical remission [24]	
Urinarysystem tumor (mainly prostate cancer)	Prostate cancer	NCT04382898	BNT112 (PAP, PSA, and three undisclosed antigens) + cemiplimab	I/II	PAP, PSA, and three undisclosed antigens	recruiting	RNA-LPX	Not published	
NCT01817738	mRNA vaccine CV9104	I/II		Terminated	Protamine	Not published	
NCT01446731	DCs transfected with PSA, PAP, survivin and hTERT mRNA + docetaxel	II	PSA, PAP, survivin and hTERT	Completed	DC	Not published	
NCT02692976	DC loaded with protamine/mRNA encoding keyhole limpet hemocyanin (KLH) + DC loading with MHC I binding peptides, NY-ESO-1 and MUC1 PepTivator®	II	keyhole limpet hemocyanin (KLH)	Completed	DC	Not published	
NCT01197625	Dendritic cell vaccine	I/II	PSA	Active, not recruiting	DC	Not published	
NCT01153113	Human telomerase reverse transcriptase mRNA (hTERT mRNA) transfected dendritic cell	I/II	hTERT	Withdrawn	DC	Not published	
NCT00831467	CV9103:PSA, PSCA, PSMA, STEAP1	I/II	PSA, PSCA, PSMA, STEAP1	Completed	Protamine	Good tolerance and immunogenicity	
NCT00831467	CV9103 (mRNA encoding 4 PSAs, PSCA, PSMA, and STEAP1)	I/II	PSAs, PSCA, PSMA, and STEAP1	Completed	protamine-stabilized mRNA	well tolerated,prolonged patient survival	
Blood System Cancer(leukemia mainly)	leukemia	NCT05000801	Dendritic cell vaccine	I	PSAs, PSCA, PSMA, and STEAP1	recruiting	DC	Not published	
NCT01686334	Dendritic cell vaccine	I/II	PSAs, PSCA, PSMA, and STEAP1	recruiting	DC	Not published	
NCT03083054	Autologous dendritic cells electroporated with WT1 mRNA	I/II	WT1	Not published	DC	Not published	
NCT00834002	Wilms Tumor Gene (WT1) mRNA-transfected autologous dendritic cell	I	WT1	Completed	DC	Not published	
NCT02649829	dendritic cell vaccination plus chemotherapy	I/II	WT1	Active, not

recruiting

	DC	Not published	
NCT01734304	DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65	I/II	WT1, PRAME, and CMVpp65	Completed	DC	Not published	
NCT00510133	GRNVAC1 (mRNA encoding human telomerase reverse transcriptase (hTERT) and a portion of the lysosome-associated membrane protein LAMP-1 (LAMP))	II	hTERT, LAMP-1 (LAMP)	Completed	DC	Not published	
NCT02528682	MiHA mRNA-loaded PD-L-silenced DC	I/II	WT1	Completed	DC	Not published	
NCT01686334	Autologous WT1 mRNA-electroporated DCs	II	WT1	Recruiting	DC	Not published	
NCT01995708	CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells (LCs)	I	CT7, MAGE-A3, and WT1	Active, recruiting	DC	safe and therapeutic

with a slight adverse event [24]

	
NCT03083054	Autologous dendritic cells electroporated with WT1 mRNA	I/II	WT1	Active, not

recruiting

	DC	Not published	
NCT00965224	mRNA encoding for Wilms’ tumor antigen WT1	II	WT1	Recruiting	DC	Not published	
NCT00514189	mRNA in AML cell lysate	I	WT1	Recruiting	DC	Not published	
NCT02405338	mRNA encoding WT1 and PRAME	I/II	WT1	Active, not

recruiting

	DC	Not published	
Digestive System Cancer	Colorectal Cancer with Liver Metastases	NCT05533697	mRNA-4359 (mRNA

encoding IDO and PD-L1)

	I/II	IDO	Recruiting	Unknown	ongoing	
NCT00228189	CEA mRNA-loaded DCs	I/II	CEA	Completed	DC	Not published	
Neurological tumors	Glioblastoma	NCT03688178	Cytomegalovirus pp65-LAMP + temozolomide, varlilumab, and Td	II		Recruiting	DC	Not published	
NCT00639639	Cytomegalovirus pp65-LAMP + autologous lymphocyte transfer and Td	I	pp65-LAMP	Completed	DC	Not published	
NCT04573140	Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)	I	LAMP	Recruiting	RNA-LPX	Not published	
NCT02649582	Dendritic cell vaccine + temozolomide chemotherapy	I/II	WT1	Recruiting	DC	No	
NCT01291420	WT1 mRNA-electroporated autologous dendritic cell	I/II	WT1	Unknown	DC	No	
NCT00961844	mRNA encoding hTERT, survivin, and tumor mRNA	I/II	hTERT	Recruiting	DCs loaded and ex vivo T cell expansion and reinfusion	Not published	
NCT02366728	Human CMV pp65-LAMP mRNA-pulsed autologous DCs	II	pp65-flLAMP	Active, not recruiting	DC	Not published	
NCT03548571	Dendritic cell immunization + Adjuvant temozolomide	II/III		Active,not recruiting	DC	Not reported	
Other Cancers	unresectable/metastatic/recurrent head and neck cancer	NCT04534205	BNT113 (mRNA encoding E6/E7)	II	E6/E7	Active, not recruiting	LPX	Not published	

mRNA vaccines encoding TSAs

During the carcinogenesis process, malignant cells develop somatic mutations, resulting in the expression of protein sequences that are not expressed in normal cells. Proteasomes can convert these proteins into peptides. Thereafter, the peptides produced can bind to MHC-I receptors and be recognized as new antigens by T-cell receptors. These novel antigens are distinct to each patient, representing tumor specificity and providing opportunities for tumor-targeted therapies [25, 155]. The specific process procedure involves removing a single tumor and identifying specific novel antigens via next-generation sequencing. The new antigens encoded by mRNAs are subsequently injected into the same patient, eliciting an immune response that can attack the tumor [156]. mRNA can encode several antigens, resulting in the presentation of many epitopes. mRNA can express multiple neoantigens, either as individual molecular forms or concatenated forms of multiple coding sequences. Some tumor types can produce a large number of novel antigens, and expressing multiple epitopes may stimulate T cell responses from a perspective of inducing a broad immune response. The most critical aspect of this therapy is verifying the precise immunogenic non-synonymous somatic mutation found in the patients' tumors and discovering new gene expression epitopes. Interestingly, in a clinical trial (NCT03394937), 20 postoperative (IIc, III, and IV) melanoma patients received an intranasal injection of non-formulated mRNA vaccine (ECI-006) [32]. The results indicated that patients tolerated the low-dose mRNA vaccination (600 μg) well and experienced a significant immunological response. No adverse reactions of level 3 or higher were noted [32]. In a second study cohort (NCT03394937), patients with metastatic melanoma in stable condition following conventional treatment for 3–12 months were given ECI-006 vaccination and standard anti-PD-1 treatment, but the results have yet to be announced [32]. Some clinical trials have reported persistent objective reactions in cancer patients following treatment without unmanageable toxic effects (NCT03323398, NCT03480152, etc.) [24, 26] (Table 4). Table 4 Clinical trials of neoantigen mRNA vaccines

Cancer type	NCT number	Drug administration	Phase	Neoantigen	Status	Delivery system	Result	
Respiratory system tumors (mainly non-small cell lung cancer)	non-small cell lung cancer	NCT03908671	Personalized mRNA vaccine encoding neoantigen	I	Individual tumour mutations	Not yet recruiting	LPP(liposubcutaneousplex)nanodelivery	Not published	
NCT03948763	mRNA-5671 (KRAS gene driver mutations) + pembrolizumab	I	KRAS gene driver mutations	Recruiting	Lipid nanoparticles	Not published	
Skin tumor (mainly melanoma)	melanoma	NCT03897881	mRNA-4157 (personalised cancer vaccine encoding 20 different mutated neoepitopes) + With pembrolizumab	II	20 different mutated neoepitopes	Active,not recruiting	Lipid nanoparticles	Not published	
NCT03480152	(NCI)-4650, a mRNA-based, personalized cancer vaccine	I	Immunogenic T-cell epitopes derived from neoantigens	Terminated	Naked mRNA	Mutation-specific CD4 + and CD8 + T-cell responses against predicted neoepitopes in three (75%) of four patients.No objective clinical responses [24, 26]	
NCT02035956	An individualised tumour mutation signature with ten selected neoepitopes for each patient	I	Ten selected neoepitopes for each patient	Completed	Naked mRNA	Out of 125 selected new epitopes, 60% can stimulate T cell responses; Good tolerance to vaccination	
	NCT03480152	NCI-4650	I/II	Immunogenic neoantigens	Active, not recruiting	LNP	safe with a slight adverse event	
NCT03468244	personalized mRNA tumor vaccine	NA	Individual tumour mutations	Recruiting	LPP	Not published	
Urinary system tumor (mainly prostate cancer)	Prostate cancer	NCT03289962	BNT122 (personalised cancer vaccine encoding individual tumour mutations)	I	Individual tumour mutations	Active, not recruiting	RNA-LPX	Good tolerance when used in combination with atezumab; Inducing the release of pro-inflammatory cytokines and peripheral T cell responses in most patients [25]	
Blood System Cancer(leukemia mainly)	leukemia	NCT03468244	Personalized mRNA vaccine encoding neoantigen	I	Individual tumour mutations	Recruiting	LPP (lipo subcutaneous plex) nanodelivery	Not published	
NCT04486378	BNT122 (personalised cancer vaccine encoding individual tumour mutations)	II	Individual tumour mutations	Recruiting	RNA-LPX	Not published	
Digestive System Cancer	Colorectal Cancer with Liver Metastases	NCT04161755	BNT122 (personalised cancer vaccine encoding individual tumour mutations) With oxaliplatin, irinotecan, fluorouracil, leucovorin, and atezolizumab	I	Individual tumour mutations	Active, not recruiting	RNA-LPX	Not published	
Esophagus Cancer	NCT03480152	National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine	I/II	Individual tumour mutations	Terminated	Lipid nanoparticles	It has safety and immunogenicity, with a maximum tested dose of 0.39 mg and no serious side effects observed	
Colorectal

Cancer

	NCT04534205	BNT122 (personalised cancer vaccine encoding individual

tumour mutations)

	II	Individual tumour mutations	Recruiting	RNA-LPX	Not published	
Pancreatic

cancer

	NCT02316457	BNT-114 plus BNT-122 (personalised set of pre-manufactured

non-mutated shared tumour-associated antigens plus a

personalised cancer vaccine encoding individual tumour mutations)

	I	Individual tumour mutations	Active, not recruiting	DC	Not published	
	gastric cancer, esophageal cancer, and liver cancer	NCT05192460	neoantigen tumor vaccine	I	individual tumour mutations	Active, not recruiting	Unknown	Not published	
	colonic neoplasms and colorectal neoplasms	NCT05456165	GRT-C901/GRTR902	II	Deoxyribonucleic acid (DNA) mutations present peptides	Recruiting	Chimpanzee adenovirus	Ongoing	
Other Cancer	TNBC	NCT02316457	IVAC_W_bre1_uID and IVAC_M_uID	I	Tumor-specific mutations	Active, not recruiting	LPX	Ongoing	

mRNA vaccines targeting tumor-associated viruses

Tumor viruses are a class of viruses capable of inducing and promoting carcinogenesis in host cells [157]. Currently, the main viruses associated with human tumors include hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), human papillomavirus (HPV), and human T-lymphotropic virus type 1 (HTLV-1) [158]. In recent years, significant progress has been made in mRNA vaccine research targeting HPV. Zhou et al. developed an mRNA-based vaccine against the late oncoproteins E6 and E7 of HPV16, which are abundantly expressed in high-grade squamous intraepithelial lesions (HSIL). In vitro and in vivo studies demonstrated that the translated mRNA was functional and elicited antigen-specific adaptive immune responses. Mice with HPV16 + lesions exhibited tumor growth inhibition, extended lifespan, and the development of protective immune memory following vaccination [159]. Hepatitis B virus (HBV) infection is a major pathogenic factor for liver cancer [160]. Research has shown that mRNA vaccines can activate the innate immune system, inducing the production of potent immunogenicity, high levels of virus-specific antibodies, memory B cells, and T cells, offering prospects for functional cure and prevention of HBV recurrence in chronic patients. However, further in-depth evaluation of mRNA vaccines is needed [161]. HIV infection increases the risk of certain tumors, such as Kaposi's sarcoma and non-Hodgkin's lymphoma [162]. Xie et al. [163] utilized mRNA technology to induce the generation of broadly neutralizing antibody (bnAb) precursors essential for multiple HIV subtypes, providing evidence for the feasibility of germline targeting (GT) and progressive immunization strategies in HIV vaccine development. Through animal models, researchers have successfully elicited specific immune responses to HIV bnAbs, providing new strategies for the development of effective HIV vaccines (Table 5). Table 5 Clinical trials of mRNA vaccines targeting tumors associated viruses

Cancer type	NCT number	Drug administration	Phase	Viruse	Status	Delivery system	Result	
Reproductive system tumors	cervical carcinoma	NCT06273553	RG002 Injection (an mRNA Therapeutic Vaccine)	I	HPV16/18	Not yet recruiting	Lipid nanoparticles	Not published	
NCT02116920	mRNA E6/E7	I	HPV genotypes 16, 18, 31, 33 and 45	Not yet recruiting	Lipid nanoparticles	Unknown	
	NCT05119855	mRNA-1273 Vaccine	IV	9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)	Completed	Lipid nanoparticles	Not published	
Skin tumor	Kaposi's sarcoma	NCT05217641	BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA or BG505 MD39.3 gp151 CD4KO mRNA	I	HIV	Active,not recruiting	Lipid nanoparticles	Not published	
NCT02413645	TriMix 100, TriMix 300	I	HIV	Completed	Lipid nanoparticles	The vaccine was secure and well tolerated. There were 31 grade 1/2 and 1 grade 3 adverse events, mostly unrelated to the vaccination. Patients who received the highest dose showed a moderate increase in T-cell responses spanning HTI sequence at week 8. In addition, the proportion of responders receiving any dose of HTI increased from 31% at w0 to 80% postvaccination. The intervention had no impact on caHIV-DNA levels, however, caHIV-RNA expression and usVL were transiently increased at weeks 5 and 6 in the highest dose of iHIVARNA, and these changes were positively correlated with HIV-1-specific-induced immune responses.	
NCT00833781	mRNA-transfected autologous dendritic cells	I	HIV	Completed	DC	There were no differences in interferon-gamma enzyme-linked immunospot responses to HIV-1 Gag or Nef in the vaccine or placebo group. CD4 proliferative responses to KLH increased 2.4-fold (P = 0.026) and CD8 proliferative responses to KLH increased 2.5-fold (P = 0.053) after vaccination. There were increases in CD4 proliferative responses to HIV-1 Gag (2.5-fold vs. baseline, 3.4-fold vs. placebo, P = 0.054) and HIV-1 Nef (2.3-fold vs. baseline, 6.3-fold vs. placebo, P = 0.009) among vaccine recipients, but these responses were short-lived.	
Lymphatic system tumor	Burkitt's lymphoma	NCT05144748	EBV mRNA vaccine	I	EBV	Recruiting	Lipid nanoparticles	Unknown	
Digestive System Cancer	Hepatocellular carcinoma	NCT05738447	HBV mRNA vaccine	I	HBV	Recruiting	Lipid nanoparticles	Unknown	

Adjuvants for mRNA vaccines

Adjuvants are additional immunostimulatory agents in vaccines that activate the innate immune system and provide the necessary "help" to increase the magnitude and quality of adaptive responses, thereby offering maximal protection against specific pathogens [164]. Different adjuvants can elicit various immune responses, influencing overall vaccine outcomes. Currently, the adjuvants used in mRNA vaccines generally include four categories: 1) the intrinsic adjuvant effects of mRNA vaccines; 2) mRNAs encoding immunostimulatory molecules; 3) mRNAs encoding antibodies; and 4) adjuvants for mRNA vaccines on the basis of delivery carrier components.

The intrinsic adjuvant effect of mRNA vaccines

Exogenous RNA molecules can induce immune responses in mammalian cells. Unmodified exogenous nucleotide mRNAs used to express antigens in mRNA vaccines exhibit intrinsic adjuvant activity by triggering innate immune signalling pathways. Notably, double-stranded RNA (dsRNA) can activate TLR3, while single-stranded RNA is capable of activating mouse TLR7, and RNA oligonucleotides containing thio-phosphorylated nucleotide linkages serve as ligands for human TLR8 [165]. Polyuridine (U) and short dsRNA with 5' triphosphate blunt ends can enhance immune responses through the TLR3 and retinoic acid-inducible gene (RIG)-I signaling pathways without compromising antigen expression, thus functioning as adjuvants for mRNA vaccines [166, 167]. The activation of TLRs and RIG-I signaling can induce the production of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-12, IL-1β, and interferon-alpha/beta (IFNα/β) (Fig. 1), which enhances the protective immunity required by mRNA vaccines while potentially leading to excessive inflammation [168]. Pioneering work by Kariko et al. demonstrated that unmodified RNA molecules activate TLR or RIG-I signaling pathways, triggering antiviral-like immune responses that may impair RNA translation and promote RNA degradation [15]. Nucleoside-modified mRNA can circumvent this immune activation, such as pseudouridine, which has been widely applied in mRNA vaccines [145, 165]. Recent studies indicate that the modified mRNA in the Pfizer-BioNTech BNT162b2 mRNA vaccine may be recognized by melanoma differentiation-associated protein 5 (MDA-5), triggering IFNα production and contributing to the magnitude of antigen-specific T cell and antibody responses [169].

mRNA vaccines encoding immune modulators

Immune modulators typically include cytokines, co-stimulatory molecules, and PRR agonists [170]. Immune modulators such as interferons, interleukins, lymphokines, and tumor necrosis factors play different roles in the immune system. Some trigger inflammation, whereas others support cell growth and differentiation, whereas others enhance lymphocyte functions [171]. It is crucial to restore the anti-tumor immune response by inhibiting immune suppression through the modulation of immune modulators [172]. The use of cytokines in cancer therapy has emerged as a viable treatment option in clinical settings for patients battling cancer [173]. One of the challenges associated with current immunomodulatory treatments is the occurrence of dose-related toxicity resulting from the short half-life of the administered agents, necessitating frequent dosing and systemic distribution, as exemplified by IL-12 therapy [174]. Therefore, intratumoral (IT) and intradermal (ID) injections are often used to induce local immune responses. The transient protein expression and prominent advantages of local delivery make mRNA vaccines complementary to immune modulators, making immune modulators important targets for mRNA vaccines. IL-12, an essential cytokine, can activate CTL and NK cells. In 2018, IL-12 mRNA-LNPs were shown to be effective in hepatocellular carcinoma (HCC) treatment [175]. Due to the unique functions of each cytokine, the efficacy of single cytokine therapy in tumor treatment is limited. Therefore, a combination of multiple cytokines with different functions is often used to improve therapeutic outcomes. Research indicates that mRNA vaccines encoding IL-12 and IL-27 can induce NK and CD8 + T cells within the melanoma tumor microenvironment (TME), demonstrating optimal efficacy [176]. Another study found that a mixture of IL-12, GM-CSF, IL-15, and IFN-α mRNA increased the number of CD4 + T cells and CD8 + T cells in the TME, and adding anti-PD-1 antibody improved mouse survival rates [136]. In 2019, Haabeth et al. [177] pioneered a novel approach to initiate anti-cancer immunity by combining cytokines with co-stimulatory molecules using mRNA. They used a specialized mRNA delivery system to locally express cytokines (CD70, IL-12, and IFN-γ) and co-stimulatory molecules (OX40L, CD80, and CD86) in two tumor models (B-cell lymphoma and colorectal cancer.). Their findings showed that mice given mRNA vaccines containing both cytokines and co-stimulatory molecules achieved complete elimination of tumors, unlike those given other mRNA vaccines that only had partial effects. Combining OX40L with CD80 or CD86, or OX40L with IL-12, notably improved survival rates and delayed tumor growth. These preclinical results indicate that specific cytokines and co-stimulatory molecules could effectively enhance T cell responses against cancer. Currently, most clinical trials on mRNA vaccines encoding immune modulators are in phase I/II to evaluate tolerability. One of the pioneers in this field is eTheRNA, which has developed an adjuvant based on TriMix mRNA consisting of three naked mRNA molecules. Both naked TriMix mRNA evaluated in multiple clinical trials and TriMix mRNA loaded onto DCs ex vivo have shown good tolerability and immunogenicity. Moderna, a leading biotech firm, has created two mRNA therapies enclosed in LNP frameworks to trigger immune responses within tumors. These therapies are undergoing phase I clinical trials to assess the safety and tolerance of repeated administration. One of the products, mRNA-2416, contains mRNA encoding OX40L. It is being tested alone or combined with the intravenous PD-L1 inhibitor durvalumab for treating lymphoma and metastatic ovarian cancer (NCT03323398) [154]. Another candidate, mRNA-2752, comprises OX40L/IL-23/IL-36γmRNA for the treatment of lymphoma (NCT03739931) [178]. Here, OX40L generates secondary signals, enhancing T-cell effector functions and promoting T-cell proliferation and survival. Moderna and AstraZeneca have teamed up to work on the development of MED I1191, which is an IL-12 mRNA product designed for intratumoral administration as part of cancer treatment. Preliminary results from the initial clinical trial revealed that sequential or combination therapy of MED I1191 with durvalumab in patients with advanced solid tumors and skin or subcutaneous lesions is safe and feasible. No treatment-related adverse events leading to treatment discontinuation from MEDI1191 or durvalumab were reported. The combination of MEDI1191 and durvalumab has demonstrated preliminary clinical efficacy; 29.0% of patients achieve either a partial response (PR) or stable disease (SD) for a minimum duration of 12 weeks (NCT03946800) [179] (Table 6). Table 6 Clinical trials of mRNA vaccines encoding immunomodulator

Cancer type	NCT number	Drug administration	Phase	Immunomodulator	Status	Delivery system	Result	
Respiratory system tumors (mainly non-small cell lung cancer)	non-small cell lung cancer	NCT02688686	Suppressor of cytokine signaling (SOCS) 1, MUC1 and Survivin mRNA-loaded DC + cytokine-induced killer	I/II	suppressor of cytokine signaling (SOCS) 1	Unknown	DC	No	
Skin tumors	Melanoma	NCT01066390	TriMix-DC	I	TLR4, CD40L and CD70	Completed	DC	15 patients had good tolerance, 2 patients had complete remission, and 2 patients had partial remission; It has immunogenicity and long-lasting anti-tumor activity for disease control. Antigen specific CD8 + T cells were detected in 4 out of 5 patients [24]	
NCT00204607	mRNA + GM-CSF	I/II	GM-CSF	Completed	Naked RNA	Not reported	
NCT00204516	mRNA coding for melanoma associated antigens + GM-CSF	I/II	GM-CSF	Completed	Naked mRNA	Not published	
NCT01278940	mRNA-transfected DCs + IL-2	I/II	IL-2	Completed	DC	Not reported	
NCT01530698	autologous dendritic cell vaccine by mRNA Electroporation	I/II	TLR7/8, IL-6	Completed	DC	Not reported	
NCT04335890	Vaccination with IKKb matured Dendritic Cells	I	IL-1ß, IL-6 and PGE2	Active,not recruiting	DC	Not reported	
NCT03394937	CD40L, CD70, TLR4; tumour-associated antigens: tyrosinase, gp100, MAGE-A3, MAGE-C2, and PRAME	I	CD40L, CD70, TLR4;	Terminated	DC	Good tolerance, low dose (600 μ g) 4/10 and 3/9 of patients with high (1800ug) levels detected vaccine induced immune responses, with immunogenicity in some patients; No adverse reactions of level 3 or above have occurred [32]	
NCT01676779	mRNA; b.TAAs: MAGE-A3, MAGE-C2, tyrosinase, gp100	II		Completed	DC	Good tolerance (symptoms: transient local skin reactions, flu like symptoms, shivering after infusion), and may increase the one-year survival rate (71% in the treatment group, 35% in the control group)	
NCT03291002	CV8102: TLR7/8, RIG-1	I	TLR7/8, RIG-1	Active,not recruiting	Protamine	Both individual and combined administration showed good therapeutic effects, and local induced immune responses were observed to transform into systemic immune responses	
Solid Tumor		NCT03946800	MEDI1191 (mRNA encoding IL-12)	I	IL-12	Recruiting	LNP	Preliminary results from the initial clinical trial revealed that sequential or combination therapy of MED I1191 with durvalumab in patients with advanced solid tumors and skin or subcutaneous lesions is safe and feasible. No treatment-related adverse events leading to treatment discontinuation from MEDI1191 or durvalumab were reported. The combination of MEDI1191 and durvalumab has demonstrated preliminary clinical efficacy; 29.0% of patients achieve either a partial response (PR) or stable disease (SD) for a minimum duration of 12 weeks [179]	
NCT04455620	BNT151 (mRNA encoding

IL-2)

	I/II	IL-2	Recruiting	LPX	Ongoing	
NCT04710043	BNT152 (mRNA encoding

IL-7) plus BNT153 (mRNA encoding IL-2)

	I	IL-7/IL-2	Recruiting	LPX	Ongoing	
NCT05392699	ABOD2011 (mRNA encoding IL-12)	I	IL-12	Recruiting	Naked-mRNA	Ongoing	
Neurological tumors(mainly glioblastoma)	glioblastoma	NCT03396575	TTRNA-DC vaccines with GM-CSF	I	GM-CSF	Recruiting	DC	No	
NCT02465268	HCMV pp65-shLAMP or pp65-flLAMP + temozolomide, GM-CSF, and Td	II	GM-CSF	Recruiting	DC	Not published	
NCT04963413	Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-LAMP plus GM-CSF	I	GM-CSF	Active,not recruiting	DC	Not published	
NCT00626483	CMV pp65-LAMP mRNA-loaded DC + GM-CSF	I	CMV pp65-LAMP	Completed	DC	Not published	
NCT03927222	Human CMV pp65-LAMP mRNA-pulsed autologous DCs + temozolomide + tetanusdiphtheria toxoid + GM-CSF	II	CMV pp65-LAMP	Recruiting	DC	Not published	
Urinarysystem tumor (mainly prostatecancer)	Prostate cancer	NCT02452307	Peptide vaccine + montanide ISA-51 + / − GM-CSF + / − imiquimod + / − mRNA/protamin	I/II	GM-CSF	Unknown	Protamine	No	
Blood System Cancer(leukemia mainly)	leukemia	NCT00514189	Autologous dendritic cells	I	GM-CSF	Terminated	DC	No	
NCT02693236	Adenovirus-transfected autologous DCs + CIK cells	I/II	cytokine-induced killer (CIK) cell	Unknown	DC	No	
Digestive System Cancer	Colorectal Cancer with Liver Metastases	NCT04157127	Pancreatic adenocarcinoma mRNA and lysate With standard therapy	I	Th-1	Recruiting	DC	No	
NCT03323398	mRNA-2416:OX40L	I/II	OX40L	Active, not recruiting	Lipid nanoparticles	Good safety and tolerability, with no occurrence of > Level 3 adverse reactions; 14/39 patients were in stable condition, and 4/6 patients with ovarian cancer were in stable condition. The patients receiving treatment showed that OX40L protein and T cell infiltration in the tumor microenvironment increased, PD-L1 transcription was up-regulated, and the expression of proinflammatory genes was activated [154].	
Colon Cancer

Gastrointestinal Cancer

	NCT03739931	mRNA-2752:OX40L, IL-23, IL-36Y	I	OX40L, IL-23, IL-36Y	Recruiting	Lipid nanoparticles	Good tolerance; Tumor shrinkage is related to drug use. 0.5 mg RNA combined with Duvalimab, 81% of bladder cancer focus regression was observed; Treatment has a sustained immune regulatory effect, with elevated levels of IFN-y, TNF-a, and PD-L1 detected in tumors and plasma [178].	
Other Cancer	Ductal carcinoma in situ	NCT02872025	mRNA-2752 (mRNA

encoding OX40L, IL-23, and IL-36γ)

	I	OX40L, IL-23, and IL-36γ	Recruiting	LNP	well tolerated with slight dose-limiting toxicities	

mRNA vaccines encoding antibodies

Since the development of monoclonal antibodies (mAb) using hybridoma technology in 1975, antibodies have risen to prominence as a rapidly expanding category of pharmaceuticals that specifically target cancer cells [180]. These antibodies have anti-tumor effects through mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and blockade of immunosuppressive signals. Conventional antibodies consist of Fab and Fc fragments, with Fab binding to tumor antigens and the Fc region interacting with FcγR on NK cells and macrophages to facilitate cancer cell lysis. In addition to traditional antibodies, single-chain variable fragments (scFvs), single-domain antibodies (sdAbs), and bispecific antibodies (bsAbs) have demonstrated potential in immunotherapy. BsAbs can form T-cell–bsAb–tumor cell complexes, mediating immune cell-mediated killing [181]. Researchers at CureVac studied mRNA vaccines targeting antibodies. After 9 years, they were able to develop mRNA vaccines targeting antibodies that effectively reduced tumor growth in a mouse lymphoma model, supporting the use of mAb-targeting mRNA vaccines in cancer immunotherapy [182]. Leiba-Kasper and colleagues conducted a study to explore the intricate relationship between the absorption, distribution, metabolism, and excretion of the mRNA-encoded anti-HER2 antibody trastuzumab, elucidating its impact on the body and its ability to combat cancer. Through their research, they confirmed the potent anticancer properties of this novel therapeutic approach, shedding light on the mechanisms underlying its efficacy in targeting HER2-positive tumors. The findings from this investigation serve to validate the promising therapeutic potential of mRNA-encoded antibodies in the fight against cancer, opening new avenues for optimized treatment strategies and improved patient outcomes [183]. In addition to monoclonal antibodies, a range of mRNA-encoded bispecific antibodies (bsAbs) have been developed. CCL2 and CCL5 play critical roles in tumor-associated macrophage (TAM) accumulation and HCC immunosuppression. The Wang group developed the bispecific antibody BisCCL2/5i, which targets CCL2 and CCL5, promoting TAM polarization towards the anti-tumor M1 phenotype and reversing immune suppression in the tumor microenvironment (TME). BisCCL2/5i sensitizes HCC to PD-L1 blockade and prolongs survival in a murine model of liver malignancy [184].Bi-specific T cell engagers (BiTEs) are a class of bispecific antibodies lacking an Fc region, consisting of two scFv domains—one recognizing CD3 and the other binding to the cancer cell target antigen—facilitating T cell-mediated tumor killing [185]. The Staid team has developed the RiboMab platform, which includes BiTE mRNA targeting three tumor-associated antigens (TAA)—CD3 × CLDN6, CLDN18.2 × CD3, and EpCAM × CD3. The mRNA encoding CD3 × CLDN6 BiTE exhibits a longer half-life in serum compared to the protein counterpart, leading to complete tumor regression in a mouse model without eliciting systemic immune reactions [186]. CD3 × CLDN6 mRNA (BNT142) is currently undergoing Phase I/II clinical trials (NCT05262530) [179]. While research on mRNA vaccine-encoded antibodies remains limited, monoclonal antibodies (mAbs) and bispecific antibodies (bsAbs) have already shown efficacy. By encoding anticancer antigens, blocking immune checkpoint molecules, and mediating T-cell anti-tumor responses through mRNA vaccine-encoded antibodies, the potential of mRNA antibody immunotherapy is vast. (Table 7). Table 7 Clinical trials of mRNA vaccines encoding Ab

Cancer type	NCT number	Drug administration 	Phase	Status 	Delivery system	Result	
Solid Tumor	NCT05262530	BNT142 (mRNA encoding antibodies targetingCD3 × CLDN6)	I 	Recruiting 	LNP	Ongoing	
Reproductive system tumors (mainly ovarian cancer)	ovarian cancer	NCT04683939	BNT141 (mRNA encodinganti-Claudin18.2 monoclonal antibody)	I/II	Recruiting 	LNP	Ongoing	

Adjuvants for mRNA vaccines based on delivery carrier components

Cationic lipids may play a critical role in the adjuvant activity of lipid nanoparticles (LNPs). LNPs based on the ionizable cationic lipid DLinDMA exhibit immunostimulatory properties and serve as adjuvants for nucleoside-modified mRNA vaccines, effectively eliciting follicular helper T (TFH) cell responses and germinal centre B-cell responses that produce neutralizing antibodies [187]. The cationic lipid-like substance C1 facilitates the delivery of mRNA into cells, promoting the release of inflammatory cytokines such as IL-1β, IL-6, and IL-12P70 and upregulating the expression of costimulatory molecules via the TLR4 signalling pathway [141]. Lipid C12-TLRa, containing a TLR7/8 agonist, enhances mRNA vaccine delivery and TLR responses, collectively inducing high levels of neutralizing antibodies [188]. Another ionizable lipid-like substance, A2-Iso5–2DC18 (A2), activates STING signaling and releases cytokines such as CXCL10, thereby enhancing the immune response [68]. The non-nucleotide STING agonist-derived amino lipid SAL12, formulated into LNPs, induces the production of IFNβ, triggering potent neutralizing antibodies against SARS-Cov-2 [189]. Additionally, the direct incorporation of all-trans retinoic acid (ATRA) during LNP self-assembly results in ATRA-LNPs that effectively activate dendritic cells, eliciting robust systemic T-cell responses and increasing the infiltration of antigen-specific cytotoxic T cells in colorectal tumors [190]. However, the intrinsic immunostimulatory properties of lipid materials are not always beneficial for vaccines. A study reported that lipid components (DOTMA and DOPE) in mRNA vaccines promote mitochondrial ROS production in monocytes, activating the NLRP3 inflammasome and releasing IL-1β, leading to inflammatory side effects [191]. These findings underscore the importance of selecting lipid components with appropriate immunostimulatory effects for the rational design and development of future mRNA vaccines.

Combined application of mRNA vaccines with other tumor targeted therapies

Currently, many patients have developed resistance to tumor-targeted monotherapies, substantially impacting the effectiveness of tumor-targeted therapy. Therefore, the combined application of mRNA vaccines with other tumor-targeted therapies holds tremendous potential in enhancing treatment outcomes. By harnessing the synergistic effects of different therapeutic approaches, this combination strategy offers a promising avenue for overcoming resistance and improving the overall efficacy of tumor-targeted therapy.

Combined application of mRNA Vaccines and Adoptive Cell Therapy (ACT)

ACT involves extracting immune-active cells from cancer patients, culturing and evaluating their function outside the body, and finally reintroducing them back into patients to target and destroy tumors directly [192]. Adoptive immune cell therapy mainly includes several categories such as TCR-T and CAR-T [193]. Currently, the most commonly used/most effective applications are CAR-T therapy and TCR-T therapy [194, 195].TCR-T cell therapy entails the isolation of T cells from the patient's body, genetic engineering to express a specific T-cell receptor (TCR), and targeting tumor-associated antigens for recognition and elimination [196]. mRNA vaccines have the ability to induce a broad immune response, encompassing humoral and cellular immunity, while TCR-T therapy allows for direct targeting and destruction of tumor cells [197]. If these two therapies are utilized in conjunction, it has the potential to enhance the anti-tumor capabilities of the innate immune system and directly target [198] specific tumor antigens, thereby demonstrating synergistic efficacy. Furthermore, as a relatively safe and repeatable administration mode, mRNA vaccines could enhance the tolerability of TCR-T cell therapy [199]. However, the joint application of mRNA vaccines and TCR-T cell therapy is still in its early exploratory phase [200].CAR-T is a novel immunotherapy approach that employs genetic engineering technology to modify T cells, allowing them to exert anti-tumor effects [201]. Specifically, CAR-T cells constitute a cutting-edge immunocellular therapy that uses genetic engineering to insert customized chimeric antigen receptors (CARs) into T cells. CARs are generated by combining exogenous antigen recognition domains with T-cell receptor domains. This fusion enables CAR-T cells to accurately target and destroy specific cancer cells. Clinical trials have demonstrated promising outcomes with CAR-T-cell therapy, providing new treatment options for cancer patients. These CAR structures consist of single-chain antibody extracellular domains, extracellular hinge domains, transmembrane domains, and intracellular domains, which facilitate their recognition and binding of specific antigens. CAR-T-cell therapy involves transfecting CAR-T cells with mRNAs encoding target proteins to produce the mRNA‒target-CAR-T complex, which is subsequently administered to the body. This therapeutic strategy has been investigated in cancer patients, and promising results have been reported. For instance, a study by Tchou et al. [202] demonstrated that T cells transfected with CAR mRNA targeting c-Met exhibited good tolerance within the breast tumor tissues and were capable of triggering an inflammatory response. This finding suggested that the combination of CAR-T-cell therapy and mRNA vaccines could be a viable treatment approach, enabling more comprehensive and precise targeting of tumors for greater tumor killing efficacy. In another study, Beatty et al. [203]evaluated T cells transfected with mRNA encoding mesothelin-directed CAR as a potential treatment for pancreatic tumors. Interestingly, in a phase 1 study, these cells did not cause CRS or trigger neurological symptoms. Previous studies have indicated that IVT mRNAs encoding TAMs can be directly delivered into tumors via CAR-T nanoparticle technology to induce local regulation of tumor-associated dendritic cells (TADCs) [204].

mRNA vaccines combined with Immune Checkpoint Inhibitor (ICI)

Immune checkpoints play crucial protective roles in regulating the human immune system, acting as brakes to prevent excessive T-cell activation and other undesirable effects. However, tumor cells frequently exploit this regulatory mechanism by overexpressing immune checkpoint molecules, which effectively dampen immune system responses, evade immunosurveillance, and promote tumor development. The most widely researched and applied ICIs include CTLA4, PD-1, and PD-L1. ICI therapy works by blocking immune checkpoint activity and activating T cells to attack tumors, leading to anti-tumor effects. Furthermore, ICIs can maintain induced immunological responses while inhibiting the induction of T-cell depletion indicators, making them useful partners for mRNA vaccines [205]. Ugur Sahin et al. [206] demonstrated that combining the melanoma mRNA vaccine FixVac with PD-1 inhibitors can result in a synergistic effect. Surprisingly, drug sensitivity can even be restored in patients who have previously developed resistance to ICI treatment using this combination treatment. This trial involved 89 advanced melanoma patients (phase IV) who were treated with at least one vaccine targeting a TAA and who had received one or more ICI therapies. All patients received 8 FixVac vaccinations. Interestingly, among them, 47 out of 89 patients (52.81%) displayed positive responses, with 42 exhibiting the best objective response and 5 exhibiting partial reactions. In addition, 3 patients achieved partial remission, 7 patients remained stable, and 1 patient achieved complete remission of the metastatic lesion among the 25 patients who received FixVac monotherapy. Moreover, among the 17 patients treated with FixVac and PD-1 inhibitors, 6 experienced partial reactions and target lesion regression at all doses. During the two-year follow-up, the majority of patients who achieved partial remission or remained stable had longer disease control. Furthermore, in another important clinical trial, researchers used the mRNA-4157/V940 vaccine in combination with pembrolizumab. The results revealed a significant decrease in the risk of disease relapse among patients who were administered combination therapy compared with those who were solely treated with PD-1 inhibitors [207]. In another study, Lina Liu et al. [208] reported that MUC1-based mRNA vaccination can successfully activate CTL responses against triple-negative breast cancer (TNBC). Furthermore, combining an mRNA vaccine with an anti-CTLA-4 monoclonal antibody can markedly enhance the T-cell immune response, and the effect was substantially superior to that of treatment with an mRNA vaccine alone or anti-CTLA-4 monoclonal antibody therapy alone. Although research on these technologies is still relatively limited, their prospects are highly promising. Furthermore, small interfering RNA (siRNA) has shown great potential in ICIs [209], which can be encapsulated in the same vector as mRNAs to prevent repeated delivery, have shown great potential in the treatment of ICIs. Although there are several limitations associated with its small molecular weight and low encapsulation efficiency, the encapsulation concentration of this therapy is still within acceptable limits.

Combination application of mRNA vaccines and oncogene therapy

Oncogene therapy often involves introducing wild-type copies of tumor suppressor genes or exploiting tumor-specific phenotypic changes to selectively target cancer cells. Tumor suppressor genes (TSGs) are essential for maintaining genomic integrity and regulating cell growth, differentiation, and apoptosis [210]. The loss of TSG function is commonly associated with the occurrence, progression, and treatment resistance of cancer [211]. Furthermore, numerous cancer driver genes, mostly TSGs, have been identified through human cancer exon sequencing studies [212]. The majority of TSGs experience functional loss, leading to overactivation of cancer phenotypes through the aforementioned pathways. In such scenarios, a potential therapeutic approach involves suppressing downstream pathways via supplementation with TSGs. However, difficulties in delivery, genomic integration, and mutation risks pose significant obstacles to gene therapy when functional copies are restored via DNA transfection. mRNA vaccines have been demonstrated to effectively address these issues. In a study from 2018, a PTEN-mRNA vaccine was encapsulated in polyethylene glycol (PEG)-coated polymer‒lipid hybrid nanoparticles (LNPs), successfully introducing PTEN-deficient prostate cancer cells. The therapeutic efficacy of inhibiting the PI3K/Akt signalling pathway and promoting cancer cell apoptosis has been validated [213]. In a study conducted in 2021, PTEN mRNA-NPs were shown to restore the protein expression and autophagy of PTEN-deficient cancer cells, demonstrating therapeutic effects against melanoma and PD-1-resistant prostate cancer [214]. While the utilization of TSG-mRNA vaccines remains largely uncharted territory, their efficacy has been demonstrated in various mouse cancer models, underscoring their considerable practical promise.

Future development trends of mRNA vaccines in tumor targeted therapy

mRNA vaccines, as an emerging immunotherapeutic modality, exhibit a diversified and promising outlook in their future development trends [215]. Here, we discussed the importance and impact of personalized vaccine design, multifunctionality, combination therapy strategies, mucosal immunity, and nanotechnology on the application of mRNA vaccines in targeted tumor therapy. Personalized mRNA tumor vaccines design stands out as a research hotspot [143]. By elucidating the genetic and immune characteristics of patient tumor cells, highly personalized mRNA tumor vaccines can be tailored for individual patients. These customized vaccines can more precisely trigger patient-specific immune responses, thereby enhancing treatment efficacy. In the future, interdisciplinary studies encompassing genomics, immunomics, and bioinformatics will provide a more precise theoretical foundation for personalized vaccine design, laying solid groundwork for clinical applications. The development of personalized vaccines will also benefit from the continuous advancement of high-throughput sequencing technologies, which will aid in the rapid and accurate detection of genomic information in individual tumors. Furthermore, the application of artificial intelligence technology will provide more support. For example, optimizing mRNA sequences via artificial intelligence technology has greatly reduced the immunogenicity of mRNA vaccines [216]. By integrating research findings from different interdisciplinary fields, the design of personalized vaccines will continue to be optimized, providing more effective treatment strategies for a vast number of cancer patients. In addition to directly activating the immune system to attack tumors, the future development trend of mRNA vaccines also includes achieving vaccine multifunctionality. These findings indicate that mRNA vaccines can also regulate the immune microenvironment, inhibit tumor growth and spread, and perform other functions. By incorporating various active components, such as immune modulators and cytokines, mRNA-based tumor vaccines will gradually achieve comprehensive intervention against tumors, suggesting new possibilities for cancer treatment [153]. Future research will focus on deciphering the interaction mechanisms of different components in vaccines to achieve more precise and efficient therapeutic effects. Simultaneously, through techniques such as gene editing, the active components in vaccines may undergo more precise regulation, further enhancing the multifunctional effects of the vaccines. Research on multifunctional vaccines will provide broader insights for the development of personalized treatment strategies. In the context of mRNA-based tumor vaccines, the integration of multiple therapeutic modalities is foreseen to emerge as a pivotal and compelling avenue for improvement [217]. The combination of mRNA vaccines with other anti-tumor treatment modalities holds the promise of further enhancing the therapeutic efficacy of vaccines and achieving synergistic effects via multiple treatment mechanisms. In the future, interdisciplinary research teams will conduct more basic research and clinical trials to explore the mechanisms and application prospects of combined therapeutic strategies in tumor treatment. Interdisciplinary collaboration has become a key approach in the study of combined therapeutic strategies, involving experts from multiple disciplines, including immunology, cell biology, pharmacology, and others. Research on combined therapeutic strategies not only requires a deep understanding of the mechanisms of different treatment modalities but also aims to explore how to rationally combine these modalities to achieve optimal effects in the treatment of tumors at different stages. Mucosal immunology, as a new direction in mRNA tumor vaccine research, has garnered significant attention [218]. By guiding immune responses in local mucosal tissues and designing specific mucosal antigens and adjuvants, prevention and treatment of tumors can be achieved. The introduction of mucosal immunization strategies will lead to novel ideas and possibilities in the field of tumor prevention and control, providing broader insights for the research and application of future tumor vaccines. In future research on mucosal immunology, a deeper exploration of the characteristics of mucosal immune tissues and their relevance to tumor-targeted therapy will be carried out. Additionally, customized mucosal immune vaccines are crucial for enhancing the delivery efficiency and immune effects of vaccines in mucosal immune tissues. Furthermore, interdisciplinary collaborations will open new avenues for the application of mucosal immunization in tumor vaccines. The application of nanotechnology in mRNA tumor vaccines has also attracted considerable attention. Nanocarriers can safely and effectively deliver mRNA vaccines into the body, increasing their bioavailability and immunogenicity [219]. Concurrently, the targeted drug delivery and reduced side effects of nanotechnology significantly increase the therapeutic efficacy and safety of tumor vaccines. The combination of nanotechnology and mRNA-based tumor vaccines will lead to the development of novel therapeutic strategies and possibilities for cancer treatment. Future developments in nanotechnology will focus on improving the stability and targeting of carriers, further reducing their metabolism and excretion rates in the body, thereby prolonging the vaccine's efficacy and impact. Additionally, nanotechnology can provide more possibilities for the modification and functionalization of vaccines to meet the diverse treatment needs of different tumor types and individual patients. The application of nanotechnology in mRNA tumour vaccines will introduce more precise and efficient therapeutic approaches to the field of cancer treatment. Despite the significant potential of mRNA vaccines in targeted cancer therapy, several limitations persist: 1) Poor stability: the chemical structure and biological properties of mRNAs render them inherently unstable and susceptible to degradation, which affects their biological activity and immunogenicity [220]. Although chemical modifications can increase stability, their efficacy is limited, with studies indicating that N1-methylpseudouridine-modified mRNAs undergo ribosomal frameshifting during translation [221]. 2) Low in vivo delivery efficiency: The safe and effective delivery of mRNA to target cells is crucial for its functionality [222]. Current delivery systems, such as liposomes and lipid nanoparticles, have improved in stability and intracellular delivery [67], yet the efficiency of delivery remains suboptimal [152]. 3) Complex tumor immune evasion mechanisms: Tumor cells employ multiple strategies to evade immune surveillance [223], presenting a challenge in the field of mRNA vaccine-based targeted cancer therapy [24]. 4) High interindividual variability: Differences in genetic background, immune status, and disease conditions among individuals influence the immunogenicity and therapeutic efficacy of mRNA vaccines [224]. Based on the aforementioned limitations, we advocate for the following enhancements to mRNA vaccines: Firstly, the essence of mRNA vaccines lies in harnessing the endogenous cellular machinery for antigen protein synthesis to trigger immune responses. The optimization of mRNA structure and sequence can significantly enhance its stability and transcriptional efficiency [216, 225]. Researchers have improved mRNA expression levels and duration within cells by refining the 5' cap structure, 3' poly(A) tail, codon usage, and nucleotide modifications [154, 215, 226]. Secondly, beyond optimizing the mRNA itself, the adoption of novel delivery systems is pivotal for enhancing the immunogenic efficacy of mRNA vaccines. Consequently, the development of safer and more effective new carriers is imperative. Emerging lipid nanomaterials, such as biodegradable fatty acid nanoparticles, have demonstrated superior targeting and immunogenicity in animal models [227]. Similarly, as previously noted, biomimetic carriers can enhance the efficiency and intensity of vaccine mRNA translation compared to conventional materials [113].Finally, for mRNA to be translated into antigen proteins, it must successfully traverse into the cytoplasm of target cells, a process fraught with challenges such as lysosomal degradation post-endocytosis or nuclease degradation [228].Therefore, enhancing mRNA stability and penetrance is crucial [229]. For example, physical methods like electroporation can temporarily disrupt the cell membrane, thereby facilitating increased mRNA transport efficiency [230]. We also discuss key points to consider in the clinical translation of mRNA vaccine technology. First, there is a critical need to strengthen preclinical research to thoroughly investigate the biological characteristics of the vaccine, including its stability, immunogenicity, and routes of administration, to ensure its safety and efficacy. Second, conducting large-scale randomized controlled trials is essential for validating the differences between mRNA vaccines and traditional vaccines, particularly in terms of administration routes, dosage design, and immunogenicity. Furthermore, addressing immune responses across different populations can provide scientific evidence for the precise use of vaccines, ensuring their preventive efficacy and safety. Third, the assessment of long-term efficacy and safety is vital. Continuous monitoring of the duration of immunity and potential adverse reactions postvaccination, especially rare severe events, is necessary to obtain long-term immunogenicity, protective efficacy, and safety data through systematic follow-up analysis, thus providing a reliable basis for clinical applications. Finally, optimizing the design of clinical trial protocols is essential to increase the scientific rigor and reliability of trials. The administration routes and treatment regimens should be flexibly designed according to the characteristics of the vaccine, and trial standards and observational indicators should be optimized on the basis of the immunological characteristics of different populations, with endpoint indicators determined in conjunction with epidemiological considerations.

Conclusion

mRNA vaccines represent a promising solution to overcome the limitations encountered in conventional cancer immunotherapy, offering enhanced and durable treatment alternatives. We posit that the integration of mRNA vaccine technology into tumor-targeted therapy will yield expanded applications, serving as an effective tool in the battle against cancer. The versatility of mRNA vaccines, coupled with their ability to elicit immune responses targeting specific tumor antigens, holds great potential for personalized cancer treatment strategies. As research continues to advance in this area, it is conceivable that mRNA vaccines will play a pivotal role in tumor-targeted therapy.

Abbreviations

mRNA Messenger ribonucleic acid

ICI Immune checkpoint inhibitors

SAM Self-amplifying

ORF Open reading frame

NSP Non-structural protein

UTR Untranslated region

IVT In vitro transcription

TLR Toll like receptors

dsRNA Double-stranded RNA

HPLC High performance liquid chromatography

FPLC Fast protein liquid chromatography

ARCA Anti-Reverse Cap Analog

DC Dendritic cells

CNE Cationic nanoemulsion

CPP Cationic cell penetrating peptides

LNP Lipid nanoparticle

LP Liposomes

DSPC Double stearyl phosphatidylcholine

PEI Polyethylene imine

PAMAM Polyamide amine

PPI Pol (propylene imine)

PAE Poly (amino ester)

PEG Polyethylene glycol

PLGA Poly(lactic-co-glycolic acid)

PTEN Phosphatase and tensin homologue

PLA Polylatic acid

PBAE Poly β-aminoesters

PGLA POLY(D,L-LACTIDE-CO-GLYCOLIDE)

VRP Virus like replicon particle

DOTAP 1.2-Diol sn glycerol-3-phosphate choline

VEEV Venezuelan equine encephalitis virus

MHC Main Histocompatibility complex

GMCSF Granulocyte macrophage colony-stimulating factor

LPX Lipid complex

TAA Tumor associated antigens

APC Antigen presenting cell

HLA Human leukocyte antigen

BMDC Bone marrow-derived dendritic cell

OVA Ovalbumin

PRR Pattern recognition receptor

PAMP Pathogen associated molecular pattern

ssRNA Single strand RNA

TCR T cell receptor

RIG-I Cytosolic retinoic acid inducible gene I

RLR Cytosolic retinoic acid inducible gene I (RIG-I) like receptor

MDA 5 Melanoma differentiation associated gene 5

IFN Interferon

CA Carbohydrate antigen

AFP Alpha fetoprotein

CAR-T Chimeric Antigen Receptor T-Cell Immunotherapy

TADC Tumor associated dendritic cell

CTLA Cytotoxic T-lymphocyte-associated protein

PD-1 Programmed cell death protein 1

SiRNA Small interfering RNA

TME Tumor microenvironment

MDSC Myeloid suppressor cell

CAF Cancer associated fibroblast

NK cell Natural killer cell

TIPE2 Tumor necrosis factor- α Induced protein 8-like 2

TIME Tumor immune microenvironment

TNBC Triple negative breast cancer

CTLs Cytotoxic T lymphocyte

TNF Tumor necrosis factor

IL Interleukin

TFH Follicular helper T

BiTEs Bi-specific T cell engagers

scFvs Single-chain variable fragments

sdAbs Single-domain antibodies

bsAbs Bispecific antibodies

ADCP Antibody-dependent cellular phagocytosis

CDC Complement-dependent cytotoxicity

mAb Monoclonal antibodies

bnAb Broadly neutralizing antibody

HSIL High-grade squamous intraepithelial lesions

HBV Hepatitis B virus

HCV Hepatitis C virus

EBV Epstein-Barr virus

HPV Human papillomavirus

HTLV-1 Human T-lymphotropic virus type 1

GMCSF Granulocyte–macrophage colony-stimulating factor

EGFR Epidermal growth factor receptor

hTERT Human telomerase reverse transcriptase

NY-ESO-1 New York Esophageal Squamous Cell Carcinoma-1

MAGE Melanoma-associated antigen

LC Langerhans cell

HLA Human leucocyte antigen

PAP Prostatic Acid Phosphatase

PSA Prostate specific antigen

KLH Keyhole Limpet Hemocyanin

PSCA Prostate Stem Cell Antigen

PSMA Prostate Specific Membrane Antigen

STEAP Six-segment transmembrane epithelial antigen of prostate

WT Williams Tumor

PRAME Preferentially expressed antigen in melanoma

CMV Cytomegalovirus

LAMP1 Lysosomal Associated Membrane Protein 1

IDO Indoleamine 2,3-dioxygenase

KRAS V-Ki-ras2 Kirsten ratsarcoma viral oncogene homolog

SOCS Suppressor of cytokine signaling

CD40L CD40 Ligand

PGE2 Prostaglandin E2

CIK Cytokine-induced killer cells

OX40L TNF Receptor Superfamily Member 4 Ligand

CLDN6 Claudin-6

Acknowledgements

Not applicable.

Authors’ contributions

YG and LY conducted the research study. YG drafted the manuscript. LZ provided assistance during the revision and drafting process. XP and HL contributed to the conceptual framework, supervised the study, and revised the manuscript. All authors carefully reviewed the final manuscript and approved it for publication.

Funding

This study was supported by grants from the Basic Research Project Of Educational Department of Liaoning Province(LJKMZ20221210),Shenyang Science and Technology Plan (21–104-0–04/22–321-31–02),Shenyang Science and Technology Talent Project (RC220032), National Natural Science Foundation of China (82203680), Natural Scientific Foundation of Liaoning Province(2021-MS-176), National Natural Science Foundation of China (81472302), Natural Scientific Foundation of Liaoning Province(2022-BS-137).

Availability of data and materials

Not applicable.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yu Gao, Liang Yang and Zhenning Li contributed equally to this work.
==== Refs
References

1. Siegel RL Miller KD Wagle NS Jemal A Cancer statistics, 2023 CA Cancer J Clin 2023 73 1 17 48 10.3322/caac.21763 36633525
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.36633525 10.3322/caac.21763
2. Terai M Sato T Individualised neoantigen cancer vaccine therapy Lancet 2024 403 10427 590 591 10.1016/S0140-6736(23)02463-7 38246193
Terai M, Sato T. Individualised neoantigen cancer vaccine therapy. Lancet. 2024;403(10427):590–1.38246193 10.1016/S0140-6736(23)02463-7
3. Pérez-Herrero E Fernández-Medarde A Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy Eur J Pharm Biopharm 2015 93 52 79 10.1016/j.ejpb.2015.03.018 25813885
Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.25813885 10.1016/j.ejpb.2015.03.018
4. Verheul MK Vos M de Rond L De Zeeuw-Brouwer ML Nijhof KH Smit D Oomen D Molenaar P Bogaard M van Bergen R Contribution of SARS-CoV-2 infection preceding COVID-19 mRNA vaccination to generation of cellular and humoral immune responses in children Front Immunol 2023 14 1327875 10.3389/fimmu.2023.1327875 38193077
Verheul MK, Vos M, de Rond L, De Zeeuw-Brouwer ML, Nijhof KH, Smit D, Oomen D, Molenaar P, Bogaard M, van Bergen R, et al. Contribution of SARS-CoV-2 infection preceding COVID-19 mRNA vaccination to generation of cellular and humoral immune responses in children. Front Immunol. 2023;14:1327875.38193077 10.3389/fimmu.2023.1327875
5. Zhao GX Bu GL Liu GF Kong XW Sun C Li ZQ Dai DL Sun HX Kang YF Feng GK mRNA-based vaccines targeting the T-cell Epitope-rich domain of epstein Barr virus latent proteins elicit robust anti-tumor immunity in mice Adv Sci (Weinh) 2023 10 35 e2302116 10.1002/advs.202302116 37890462
Zhao GX, Bu GL, Liu GF, Kong XW, Sun C, Li ZQ, Dai DL, Sun HX, Kang YF, Feng GK, et al. mRNA-based vaccines targeting the T-cell Epitope-rich domain of epstein Barr virus latent proteins elicit robust anti-tumor immunity in mice. Adv Sci (Weinh). 2023;10(35):e2302116.37890462 10.1002/advs.202302116
6. Magadum A Kaur K Zangi L mRNA-Based Protein Replacement Therapy for the Heart Mol Ther 2019 27 4 785 793 10.1016/j.ymthe.2018.11.018 30611663
Magadum A, Kaur K, Zangi L. mRNA-Based Protein Replacement Therapy for the Heart. Mol Ther. 2019;27(4):785–93.30611663 10.1016/j.ymthe.2018.11.018
7. Saito T Saito T Hashimoto H Ogata K Kobayashi M Takada H Kuru S Kimura T Nakamura A Matsumura T Safety and immunogenicity of mRNA COVID-19 vaccine in inpatients with muscular dystrophy Muscle Nerve 2023 67 2 117 123 10.1002/mus.27761 36478587
Saito T, Saito T, Hashimoto H, Ogata K, Kobayashi M, Takada H, Kuru S, Kimura T, Nakamura A, Matsumura T. Safety and immunogenicity of mRNA COVID-19 vaccine in inpatients with muscular dystrophy. Muscle Nerve. 2023;67(2):117–23.36478587 10.1002/mus.27761
8. Jiang L Berraondo P Jericó D Guey LT Sampedro A Frassetto A Benenato KE Burke K Santamaría E Alegre M Systemic messenger RNA as an etiological treatment for acute intermittent porphyria Nat Med 2018 24 12 1899 1909 10.1038/s41591-018-0199-z 30297912
Jiang L, Berraondo P, Jericó D, Guey LT, Sampedro A, Frassetto A, Benenato KE, Burke K, Santamaría E, Alegre M, et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med. 2018;24(12):1899–909.30297912 10.1038/s41591-018-0199-z
9. Cao J Choi M Guadagnin E Soty M Silva M Verzieux V Weisser E Markel A Zhuo J Liang S mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease Nat Commun 2021 12 1 3090 10.1038/s41467-021-23318-2 34035281
Cao J, Choi M, Guadagnin E, Soty M, Silva M, Verzieux V, Weisser E, Markel A, Zhuo J, Liang S, et al. mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nat Commun. 2021;12(1):3090.34035281 10.1038/s41467-021-23318-2
10. Zheng X Xu H Yi X Zhang T Wei Q Li H Ai J Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine Mol Cancer 2021 20 1 160 10.1186/s12943-021-01452-1 34872584
Zheng X, Xu H, Yi X, Zhang T, Wei Q, Li H, Ai J. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine. Mol Cancer. 2021;20(1):160.34872584 10.1186/s12943-021-01452-1
11. Wolff JA Malone RW Direct gene transfer into mouse muscle in vivo Science 1990 247 4949 Pt 1 1465 1468 10.1126/science.1690918 1690918
Wolff JA, Malone RW. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–8.1690918 10.1126/science.1690918
12. Conry RM LoBuglio AF Characterization of a messenger RNA polynucleotide vaccine vector Cancer Res 1995 55 7 1397 1400 7882341
Conry RM, LoBuglio AF. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995;55(7):1397–400.7882341
13. Weissman D Ni H Scales D HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response J Immunol 2000 165 8 4710 4717 10.4049/jimmunol.165.8.4710 11035115
Weissman D, Ni H, Scales D. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol. 2000;165(8):4710–7.11035115 10.4049/jimmunol.165.8.4710
14. Nair SK Morse M Boczkowski D Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells Ann Surg 2002 235 4 540 549 10.1097/00000658-200204000-00013 11923611
Nair SK, Morse M, Boczkowski D. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg. 2002;235(4):540–9.11923611 10.1097/00000658-200204000-00013
15. Karikó K Muramatsu H Welsh FA Ludwig J Kato H Akira S Weissman D Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Mol Ther 2008 16 11 1833 1840 10.1038/mt.2008.200 18797453
Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–40.18797453 10.1038/mt.2008.200
16. Zhao X Yu YT Targeted pre-mRNA modification for gene silencing and regulation Nat Methods 2008 5 1 95 100 10.1038/nmeth1142 18066073
Zhao X, Yu YT. Targeted pre-mRNA modification for gene silencing and regulation. Nat Methods. 2008;5(1):95–100.18066073 10.1038/nmeth1142
17. Hanashiro K Ohta S Sunagawa M Modification of Cepsilon mRNA expression by EBV-encoded latent membrane protein 1 Mediators Inflamm 2006 2006 6 68069 10.1155/MI/2006/68069 17392589
Hanashiro K, Ohta S, Sunagawa M. Modification of Cepsilon mRNA expression by EBV-encoded latent membrane protein 1. Mediators Inflamm. 2006;2006(6):68069.17392589 10.1155/MI/2006/68069
18. Reiter M Walf VM Christians A Modification of mRNA expression after treatment with anabolic agents and the usefulness for gene expression-biomarkers Anal Chim Acta 2007 586 1–2 73 81 10.1016/j.aca.2006.10.049 17386698
Reiter M, Walf VM, Christians A. Modification of mRNA expression after treatment with anabolic agents and the usefulness for gene expression-biomarkers. Anal Chim Acta. 2007;586(1–2):73–81.17386698 10.1016/j.aca.2006.10.049
19. Lorenzi JC Trombone AP Rocha CD Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis BMC Biotechnol 2010 10 77 10.1186/1472-6750-10-77 20961459
Lorenzi JC, Trombone AP, Rocha CD. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol. 2010;10:77.20961459 10.1186/1472-6750-10-77
20. Van Lint S Goyvaerts C Maenhout S Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy Cancer Res 2012 72 7 1661 1671 10.1158/0008-5472.CAN-11-2957 22337996
Van Lint S, Goyvaerts C, Maenhout S. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012;72(7):1661–71.22337996 10.1158/0008-5472.CAN-11-2957
21. Pollard C Rejman J De Haes W Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines Mol Ther 2013 21 1 251 259 10.1038/mt.2012.202 23011030
Pollard C, Rejman J, De Haes W. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21(1):251–9.23011030 10.1038/mt.2012.202
22. Skowronski DM De Serres G Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N Engl J Med 2021 384 16 1576 1577 10.1056/NEJMc2036242 33596348
Skowronski DM, De Serres G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021;384(16):1576–7.33596348 10.1056/NEJMc2036242
23. Ali K Berman G Zhou H Deng W Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in adolescents N Engl J Med 2021 385 24 2241 2251 10.1056/NEJMoa2109522 34379915
Ali K, Berman G, Zhou H, Deng W. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in adolescents. N Engl J Med. 2021;385(24):2241–51.34379915 10.1056/NEJMoa2109522
24. He Q Gao H Tan D Zhang H Wang JZ mRNA cancer vaccines: Advances, trends and challenges Acta Pharm Sin B 2022 12 7 2969 2989 10.1016/j.apsb.2022.03.011 35345451
He Q, Gao H, Tan D, Zhang H, Wang JZ. mRNA cancer vaccines: Advances, trends and challenges. Acta Pharm Sin B. 2022;12(7):2969–89.35345451 10.1016/j.apsb.2022.03.011
25. Blass E Ott PA Advances in the development of personalized neoantigen-based therapeutic cancer vaccines Nat Rev Clin Oncol 2021 18 4 215 229 10.1038/s41571-020-00460-2 33473220
Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215–29.33473220 10.1038/s41571-020-00460-2
26. Cafri G Gartner JJ Zaks T Hopson K Levin N Paria BC Parkhurst MR Yossef R Lowery FJ Jafferji MS mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer J Clin Invest 2020 130 11 5976 5988 10.1172/JCI134915 33016924
Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130(11):5976–88.33016924 10.1172/JCI134915
27. Xu X Wang X Liao YP Luo L Xia T Nel AE Use of a Liver-Targeting Immune-Tolerogenic mRNA Lipid Nanoparticle Platform to Treat Peanut-Induced Anaphylaxis by Single- and Multiple-Epitope Nucleotide Sequence Delivery ACS Nano 2023 17 5 4942 4957 10.1021/acsnano.2c12420 36853930
Xu X, Wang X, Liao YP, Luo L, Xia T, Nel AE. Use of a Liver-Targeting Immune-Tolerogenic mRNA Lipid Nanoparticle Platform to Treat Peanut-Induced Anaphylaxis by Single- and Multiple-Epitope Nucleotide Sequence Delivery. ACS Nano. 2023;17(5):4942–57.36853930 10.1021/acsnano.2c12420
28. Qiu K Duan X Mao M Song Y Rao Y Cheng D Feng L Shao X Jiang C Huang H mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer NPJ Vaccines 2023 8 1 144 10.1038/s41541-023-00733-8 37773254
Qiu K, Duan X, Mao M, Song Y, Rao Y, Cheng D, Feng L, Shao X, Jiang C, Huang H, et al. mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer. NPJ Vaccines. 2023;8(1):144.37773254 10.1038/s41541-023-00733-8
29. Fang E Liu X Li M Zhang Z Song L Zhu B Wu X Liu J Zhao D Li Y Advances in COVID-19 mRNA vaccine development Signal Transduct Target Ther 2022 7 1 94 10.1038/s41392-022-00950-y 35322018
Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, Wu X, Liu J, Zhao D, Li Y. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94.35322018 10.1038/s41392-022-00950-y
30. Mu Z Haynes BF Cain DW HIV mRNA Vaccines-progress and future paths Vaccines (Basel) 2021 9 2 134 10.3390/vaccines9020134 33562203
Mu Z, Haynes BF, Cain DW. HIV mRNA Vaccines-progress and future paths. Vaccines (Basel). 2021;9(2):134.33562203 10.3390/vaccines9020134
31. Mendez-Gomez HR DeVries A Castillo P von Roemeling C Qdaisat S Stover BD Xie C Weidert F Zhao C Moor R RNA aggregates harness the danger response for potent cancer immunotherapy Cell 2024 187 10 2521 2535.e2521 10.1016/j.cell.2024.04.003 38697107
Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD, Xie C, Weidert F, Zhao C, Moor R, et al. RNA aggregates harness the danger response for potent cancer immunotherapy. Cell. 2024;187(10):2521–2535.e2521.38697107 10.1016/j.cell.2024.04.003
32. Lorentzen CL Haanen JB Met Ö Svane IM Clinical advances and ongoing trials on mRNA vaccines for cancer treatment Lancet Oncol 2022 23 10 e450 e458 10.1016/S1470-2045(22)00372-2 36174631
Lorentzen CL, Haanen JB, Met Ö, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23(10):e450–8.36174631 10.1016/S1470-2045(22)00372-2
33. Abbasi S Matsui-Masai M Yasui F Hayashi A Tockary TA Mochida Y Akinaga S Kohara M Kataoka K Uchida S Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity Mol Ther 2024 32 5 1266 1283 10.1016/j.ymthe.2024.03.022 38569556
Abbasi S, Matsui-Masai M, Yasui F, Hayashi A, Tockary TA, Mochida Y, Akinaga S, Kohara M, Kataoka K, Uchida S. Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity. Mol Ther. 2024;32(5):1266–83.38569556 10.1016/j.ymthe.2024.03.022
34. Wadhwa A Aljabbari A Lokras A Foged C Thakur A Opportunities and challenges in the delivery of mRNA-based vaccines Pharmaceutics 2020 12 2 102 10.3390/pharmaceutics12020102 32013049
Wadhwa A, Aljabbari A, Lokras A, Foged C, Thakur A. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12(2):102.32013049 10.3390/pharmaceutics12020102
35. Liu Y Li Y Hu Q Advances in saRNA vaccine research against emerging/re-emerging viruses Vaccines (Basel) 2023 11 7 1142 10.3390/vaccines11071142 37514957
Liu Y, Li Y, Hu Q. Advances in saRNA vaccine research against emerging/re-emerging viruses. Vaccines (Basel). 2023;11(7):1142.37514957 10.3390/vaccines11071142
36. De A Ko YT Why mRNA-ionizable LNPs formulations are so short-lived: causes and way-out Expert Opin Drug Deliv 2023 20 2 175 187 10.1080/17425247.2023.2162876 36588456
De A, Ko YT. Why mRNA-ionizable LNPs formulations are so short-lived: causes and way-out. Expert Opin Drug Deliv. 2023;20(2):175–87.36588456 10.1080/17425247.2023.2162876
37. Dousis A Ravichandran K Hobert EM Moore MJ Rabideau AE An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts Nat Biotechnol 2023 41 4 560 568 10.1038/s41587-022-01525-6 36357718
Dousis A, Ravichandran K, Hobert EM, Moore MJ, Rabideau AE. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nat Biotechnol. 2023;41(4):560–8.36357718 10.1038/s41587-022-01525-6
38. Perenkov AD Sergeeva AD Vedunova MV Krysko DV In vitro transcribed RNA-based platform vaccines: past, present, and future Vaccines (Basel) 2023 11 10 1600 10.3390/vaccines11101600 37897003
Perenkov AD, Sergeeva AD, Vedunova MV, Krysko DV. In vitro transcribed RNA-based platform vaccines: past, present, and future. Vaccines (Basel). 2023;11(10):1600.37897003 10.3390/vaccines11101600
39. Schlesinger D Elsässer SJ Revisiting sORFs: overcoming challenges to identify and characterize functional microproteins Febs j 2022 289 1 53 74 10.1111/febs.15769 33595896
Schlesinger D, Elsässer SJ. Revisiting sORFs: overcoming challenges to identify and characterize functional microproteins. Febs j. 2022;289(1):53–74.33595896 10.1111/febs.15769
40. Imani S Tagit O Pichon C Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact NPJ Vaccines 2024 9 1 14 10.1038/s41541-024-00807-1 38238340
Imani S, Tagit O, Pichon C. Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact. NPJ Vaccines. 2024;9(1):14.38238340 10.1038/s41541-024-00807-1
41. Javidanbardan A Messerian KO Zydney AL Membrane technology for the purification of RNA and DNA therapeutics Trends Biotechnol. 2024 42 6 714 727 10.1016/j.tibtech.2023.11.016 38212210
Javidanbardan A, Messerian KO, Zydney AL. Membrane technology for the purification of RNA and DNA therapeutics. Trends Biotechnol. 2024;42(6):714–27.38212210 10.1016/j.tibtech.2023.11.016
42. Piao X Yadav V Wang E Chang W Tau L Lindenmuth BE Wang SX Double-stranded RNA reduction by chaotropic agents during in vitro transcription of messenger RNA Mol Ther Nucleic Acids 2022 29 618 624 10.1016/j.omtn.2022.08.001 36090758
Piao X, Yadav V, Wang E, Chang W, Tau L, Lindenmuth BE, Wang SX. Double-stranded RNA reduction by chaotropic agents during in vitro transcription of messenger RNA. Mol Ther Nucleic Acids. 2022;29:618–24.36090758 10.1016/j.omtn.2022.08.001
43. Abdul Kareem ZG Yasser Al-Zamily OM Al-Khafaji NSK Purification and characterization of α-galactosidase isolated from Klebsiella pneumoniae in the human oral cavity Int J Biol Macromol 2024 261 Pt 1 129550 10.1016/j.ijbiomac.2024.129550 38244734
Abdul Kareem ZG, Yasser Al-Zamily OM, Al-Khafaji NSK. Purification and characterization of α-galactosidase isolated from Klebsiella pneumoniae in the human oral cavity. Int J Biol Macromol. 2024;261(Pt 1):129550.38244734 10.1016/j.ijbiomac.2024.129550
44. Lukavsky PJ Puglisi JD Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides RNA 2004 10 5 889 893 10.1261/rna.5264804 15100443
Lukavsky PJ, Puglisi JD. Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides. RNA. 2004;10(5):889–93.15100443 10.1261/rna.5264804
45. Goyon A Tang S Fekete S Nguyen D Hofmann K Wang S Shatz-Binder W Fernandez KI Hecht ES Lauber M Separation of plasmid DNA topological forms, messenger RNA, and lipid nanoparticle aggregates using an ultrawide pore size exclusion chromatography column Anal Chem 2023 95 40 15017 15024 10.1021/acs.analchem.3c02944 37747361
Goyon A, Tang S, Fekete S, Nguyen D, Hofmann K, Wang S, Shatz-Binder W, Fernandez KI, Hecht ES, Lauber M, et al. Separation of plasmid DNA topological forms, messenger RNA, and lipid nanoparticle aggregates using an ultrawide pore size exclusion chromatography column. Anal Chem. 2023;95(40):15017–24.37747361 10.1021/acs.analchem.3c02944
46. Yuan X, Wu Z, Guo J, Luo D, Li T, Cao Q, Ren X, Fang H, Xu D, Cao Y. Natural Wood-Derived Macroporous Cellulose for Highly Efficient and Ultrafast Elimination of Double-Stranded RNA from In Vitro-Transcribed mRNA. Adv Mater. 2024;36(22):e2303321.
47. Cho E Namgung J Lee JS Jang J Jun BH Kim DE Mesoporous silica particle as an RNA Adsorbent for facile purification of in vitro-transcribed RNA Int J Mol Sci. 2023 24 15 12408 10.3390/ijms241512408 37569783
Cho E, Namgung J, Lee JS, Jang J, Jun BH, Kim DE. Mesoporous silica particle as an RNA Adsorbent for facile purification of in vitro-transcribed RNA. Int J Mol Sci. 2023;24(15):12408.37569783 10.3390/ijms241512408
48. Ojha M Vogt J Das NK Redmond E Singh K Banna HA Sadat T Koirala D Structure of saguaro cactus virus 3' translational enhancer mimics 5' cap for eIF4E binding Proc Natl Acad Sci U S A 2024 121 4 e2313677121 10.1073/pnas.2313677121 38241435
Ojha M, Vogt J, Das NK, Redmond E, Singh K, Banna HA, Sadat T, Koirala D. Structure of saguaro cactus virus 3’ translational enhancer mimics 5’ cap for eIF4E binding. Proc Natl Acad Sci U S A. 2024;121(4):e2313677121.38241435 10.1073/pnas.2313677121
49. Wang H Rizvi SRA Dong D Lou J Wang Q Sopipong W Su Y Najar F Agarwal PK Kozielski F Emerging variants of SARS-CoV-2 NSP10 highlight strong functional conservation of its binding to two non-structural proteins, NSP14 and NSP16 Elife. 2023 12 RP87884 10.7554/eLife.87884.3 38127066
Wang H, Rizvi SRA, Dong D, Lou J, Wang Q, Sopipong W, Su Y, Najar F, Agarwal PK, Kozielski F, et al. Emerging variants of SARS-CoV-2 NSP10 highlight strong functional conservation of its binding to two non-structural proteins, NSP14 and NSP16. Elife. 2023;12:RP87884.38127066 10.7554/eLife.87884.3
50. Schuberth-Wagner C Ludwig J Bruder AK Herzner AM Zillinger T Goldeck M Schmidt T Schmid-Burgk JL Kerber R Wolter S A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1–2'O-Methylated Self RNA Immunity 2015 43 1 41 51 10.1016/j.immuni.2015.06.015 26187414
Schuberth-Wagner C, Ludwig J, Bruder AK, Herzner AM, Zillinger T, Goldeck M, Schmidt T, Schmid-Burgk JL, Kerber R, Wolter S, et al. A Conserved Histidine in the RNA Sensor RIG-I Controls Immune Tolerance to N1–2’O-Methylated Self RNA. Immunity. 2015;43(1):41–51.26187414 10.1016/j.immuni.2015.06.015
51. Ziegenhals T Frieling R Wolf P Göbel K Koch S Lohmann M Baiersdörfer M Fesser S Sahin U Kuhn AN Formation of dsRNA by-products during in vitro transcription can be reduced by using low steady-state levels of UTP Front Mol Biosci 2023 10 1291045 10.3389/fmolb.2023.1291045 38146535
Ziegenhals T, Frieling R, Wolf P, Göbel K, Koch S, Lohmann M, Baiersdörfer M, Fesser S, Sahin U, Kuhn AN. Formation of dsRNA by-products during in vitro transcription can be reduced by using low steady-state levels of UTP. Front Mol Biosci. 2023;10:1291045.38146535 10.3389/fmolb.2023.1291045
52. Inagaki M Abe N Li Z Nakashima Y Acharyya S Ogawa K Kawaguchi D Hiraoka H Banno A Meng Z Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures Nat Commun 2023 14 1 2657 10.1038/s41467-023-38244-8 37169757
Inagaki M, Abe N, Li Z, Nakashima Y, Acharyya S, Ogawa K, Kawaguchi D, Hiraoka H, Banno A, Meng Z, et al. Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat Commun. 2023;14(1):2657.37169757 10.1038/s41467-023-38244-8
53. Janowski M Andrzejewska A The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize Mol Ther Nucleic Acids 2022 29 272 284 10.1016/j.omtn.2022.07.003 35855896
Janowski M, Andrzejewska A. The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize. Mol Ther Nucleic Acids. 2022;29:272–84.35855896 10.1016/j.omtn.2022.07.003
54. Xiang K Bartel DP The molecular basis of coupling between poly(A)-tail length and translational efficiency Elife. 2021 10 e66493 10.7554/eLife.66493 34213414
Xiang K, Bartel DP. The molecular basis of coupling between poly(A)-tail length and translational efficiency. Elife. 2021;10:e66493.34213414 10.7554/eLife.66493
55. Passmore LA Coller J Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression Nat Rev Mol Cell Biol 2022 23 2 93 106 10.1038/s41580-021-00417-y 34594027
Passmore LA, Coller J. Roles of mRNA poly(A) tails in regulation of eukaryotic gene expression. Nat Rev Mol Cell Biol. 2022;23(2):93–106.34594027 10.1038/s41580-021-00417-y
56. Liu MA Zhou T Sheets RL Meyer H Knezevic I WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20–22 April 2021 Emerg Microbes Infect 2022 11 1 384 391 10.1080/22221751.2022.2026742 35001848
Liu MA, Zhou T, Sheets RL, Meyer H, Knezevic I. WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20–22 April 2021. Emerg Microbes Infect. 2022;11(1):384–91.35001848 10.1080/22221751.2022.2026742
57. Mockey M Gonçalves C Dupuy FP Lemoine FM Pichon C Midoux P mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level Biochem Biophys Res Commun 2006 340 4 1062 1068 10.1016/j.bbrc.2005.12.105 16403444
Mockey M, Gonçalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun. 2006;340(4):1062–8.16403444 10.1016/j.bbrc.2005.12.105
58. Pardi N Parkhouse K Kirkpatrick E McMahon M Zost SJ Mui BL Tam YK Karikó K Barbosa CJ Madden TD Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies Nat Commun 2018 9 1 3361 10.1038/s41467-018-05482-0 30135514
Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, Karikó K, Barbosa CJ, Madden TD, et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun. 2018;9(1):3361.30135514 10.1038/s41467-018-05482-0
59. Sahin U Karikó K Türeci Ö mRNA-based therapeutics–developing a new class of drugs Nat Rev Drug Discov 2014 13 10 759 780 10.1038/nrd4278 25233993
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–80.25233993 10.1038/nrd4278
60. Huang X Zhang G Tang T Liang T Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development Mol Cancer 2021 20 1 44 10.1186/s12943-021-01310-0 33648511
Huang X, Zhang G, Tang T, Liang T. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol Cancer. 2021;20(1):44.33648511 10.1186/s12943-021-01310-0
61. Lin H Wang K Xiong Y Zhou L Yang Y Chen S Xu P Zhou Y Mao R Lv G Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development Front Immunol 2022 13 773264 10.3389/fimmu.2022.773264 35185876
Lin H, Wang K, Xiong Y, Zhou L, Yang Y, Chen S, Xu P, Zhou Y, Mao R, Lv G, et al. Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development. Front Immunol. 2022;13:773264.35185876 10.3389/fimmu.2022.773264
62. Wang S Yang Y Li L Ma P Jiang Y Ge M Yu Y Huang H Fang Y Jiang N Identification of Tumor antigens and immune subtypes of malignant mesothelioma for mRNA vaccine development Vaccines (Basel) 2022 10 8 1168 10.3390/vaccines10081168 35893817
Wang S, Yang Y, Li L, Ma P, Jiang Y, Ge M, Yu Y, Huang H, Fang Y, Jiang N, et al. Identification of Tumor antigens and immune subtypes of malignant mesothelioma for mRNA vaccine development. Vaccines (Basel). 2022;10(8):1168.35893817 10.3390/vaccines10081168
63. Kozak M Hu J DNA vaccines: their formulations, engineering and delivery Vaccines (Basel). 2024 12 1 71 10.3390/vaccines12010071 38250884
Kozak M, Hu J. DNA vaccines: their formulations, engineering and delivery. Vaccines (Basel). 2024;12(1):71.38250884 10.3390/vaccines12010071
64. Chen W Zhu Y He J Sun X Path towards mRNA delivery for cancer immunotherapy from bench to bedside Theranostics 2024 14 1 96 115 10.7150/thno.89247 38164145
Chen W, Zhu Y, He J, Sun X. Path towards mRNA delivery for cancer immunotherapy from bench to bedside. Theranostics. 2024;14(1):96–115.38164145 10.7150/thno.89247
65. Shin MD Shukla S Chung YH Beiss V Chan SK Ortega-Rivera OA Wirth DM Chen A Sack M Pokorski JK COVID-19 vaccine development and a potential nanomaterial path forward Nat Nanotechnol 2020 15 8 646 655 10.1038/s41565-020-0737-y 32669664
Shin MD, Shukla S, Chung YH, Beiss V, Chan SK, Ortega-Rivera OA, Wirth DM, Chen A, Sack M, Pokorski JK, et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol. 2020;15(8):646–55.32669664 10.1038/s41565-020-0737-y
66. Riley RS Kashyap MV Billingsley MM White B Alameh MG Bose SK Zoltick PW Li H Zhang R Cheng AY Ionizable lipid nanoparticles for in utero mRNA delivery Sci Adv 2021 7 3 eaba1028 10.1126/sciadv.aba1028 33523869
Riley RS, Kashyap MV, Billingsley MM, White B, Alameh MG, Bose SK, Zoltick PW, Li H, Zhang R, Cheng AY, et al. Ionizable lipid nanoparticles for in utero mRNA delivery. Sci Adv. 2021;7(3):eaba1028.33523869 10.1126/sciadv.aba1028
67. Zong Y Lin Y Wei T Cheng Q Lipid Nanoparticle (LNP) enables mRNA delivery for cancer therapy Adv Mater 2023 35 51 e2303261 10.1002/adma.202303261 37196221
Zong Y, Lin Y, Wei T, Cheng Q. Lipid Nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023;35(51):e2303261.37196221 10.1002/adma.202303261
68. Miao L Li L Huang Y Delcassian D Chahal J Han J Shi Y Sadtler K Gao W Lin J Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation Nat Biotechnol 2019 37 10 1174 1185 10.1038/s41587-019-0247-3 31570898
Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, Shi Y, Sadtler K, Gao W, Lin J, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37(10):1174–85.31570898 10.1038/s41587-019-0247-3
69. Ball RL Bajaj P Whitehead KA Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization Int J Nanomedicine 2017 12 305 315 10.2147/IJN.S123062 28115848
Ball RL, Bajaj P, Whitehead KA. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization. Int J Nanomedicine. 2017;12:305–15.28115848 10.2147/IJN.S123062
70. Kumar R Santa Chalarca CF Bockman MR Bruggen CV Grimme CJ Dalal RJ Hanson MG Hexum JK Reineke TM Polymeric Delivery of Therapeutic Nucleic Acids Chem Rev 2021 121 18 11527 11652 10.1021/acs.chemrev.0c00997 33939409
Kumar R, Santa Chalarca CF, Bockman MR, Bruggen CV, Grimme CJ, Dalal RJ, Hanson MG, Hexum JK, Reineke TM. Polymeric Delivery of Therapeutic Nucleic Acids. Chem Rev. 2021;121(18):11527–652.33939409 10.1021/acs.chemrev.0c00997
71. Tenchov R Bird R Curtze AE Zhou Q Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement ACS Nano 2021 15 11 16982 17015 10.1021/acsnano.1c04996 34181394
Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–7015.34181394 10.1021/acsnano.1c04996
72. Khan OF Kowalski PS Doloff JC Tsosie JK Bakthavatchalu V Winn CB Haupt J Jamiel M Langer R Anderson DG Endothelial siRNA delivery in nonhuman primates using ionizable low-molecular weight polymeric nanoparticles Sci Adv 2018 4 6 eaar8409 10.1126/sciadv.aar8409 29963629
Khan OF, Kowalski PS, Doloff JC, Tsosie JK, Bakthavatchalu V, Winn CB, Haupt J, Jamiel M, Langer R, Anderson DG. Endothelial siRNA delivery in nonhuman primates using ionizable low-molecular weight polymeric nanoparticles. Sci Adv. 2018;4(6):eaar8409.29963629 10.1126/sciadv.aar8409
73. Ali A Ganguillet S Turgay Y Keys TG Causa E Fradique R Lutz-Bueno V Chesnov S Tan-Lin CW Lentsch V Surface cross-linking by macromolecular tethers enhances virus-like particles' resilience to mucosal stress factors ACS Nano 2024 18 4 3382 3396 10.1021/acsnano.3c10339 38237058
Ali A, Ganguillet S, Turgay Y, Keys TG, Causa E, Fradique R, Lutz-Bueno V, Chesnov S, Tan-Lin CW, Lentsch V, et al. Surface cross-linking by macromolecular tethers enhances virus-like particles’ resilience to mucosal stress factors. ACS Nano. 2024;18(4):3382–96.38237058 10.1021/acsnano.3c10339
74. Comes JDG Pijlman GP Hick TAH Rise of the RNA machines - self-amplification in mRNA vaccine design Trends Biotechnol 2023 41 11 1417 1429 10.1016/j.tibtech.2023.05.007 37328401
Comes JDG, Pijlman GP, Hick TAH. Rise of the RNA machines - self-amplification in mRNA vaccine design. Trends Biotechnol. 2023;41(11):1417–29.37328401 10.1016/j.tibtech.2023.05.007
75. Biddlecome A Habte HH McGrath KM Sambanthamoorthy S Wurm M Sykora MM Knobler CM Lorenz IC Lasaro M Elbers K Delivery of self-amplifying RNA vaccines in in vitro reconstituted virus-like particles PLoS ONE 2019 14 6 e0215031 10.1371/journal.pone.0215031 31163034
Biddlecome A, Habte HH, McGrath KM, Sambanthamoorthy S, Wurm M, Sykora MM, Knobler CM, Lorenz IC, Lasaro M, Elbers K, et al. Delivery of self-amplifying RNA vaccines in in vitro reconstituted virus-like particles. PLoS ONE. 2019;14(6):e0215031.31163034 10.1371/journal.pone.0215031
76. Fuchs JD Frank I Elizaga ML Allen M Frahm N Kochar N Li S Edupuganti S Kalams SA Tomaras GD First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag Vaccine (HVTN 090) Open Forum Infect Dis 2015 2 3 ofv082 10.1093/ofid/ofv082 26199949
Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag Vaccine (HVTN 090). Open Forum Infect Dis. 2015;2(3):ofv082.26199949 10.1093/ofid/ofv082
77. Shi Y Huang J Liu Y Liu J Guo X Li J Gong L Zhou X Cheng G Qiu Y Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses Sci Adv. 2022 8 47 eabo1827 10.1126/sciadv.abo1827 36417530
Shi Y, Huang J, Liu Y, Liu J, Guo X, Li J, Gong L, Zhou X, Cheng G, Qiu Y, et al. Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses. Sci Adv. 2022;8(47):eabo1827.36417530 10.1126/sciadv.abo1827
78. Bose S Dahat Y Kumar D Haldar S Das SK A membrane targeted multifunctional cationic nanoparticle conjugated fusogenic nanoemulsion (CFusoN): induced membrane depolarization and lipid solubilization to accelerate the killing of Staphylococcus aureus Mater Horiz 2024 11 3 661 679 10.1039/D3MH01102J 37830433
Bose S, Dahat Y, Kumar D, Haldar S, Das SK. A membrane targeted multifunctional cationic nanoparticle conjugated fusogenic nanoemulsion (CFusoN): induced membrane depolarization and lipid solubilization to accelerate the killing of Staphylococcus aureus. Mater Horiz. 2024;11(3):661–79.37830433 10.1039/D3MH01102J
79. Duan X Zhang Y Guo M Fan N Chen K Qin S Xiao W Zheng Q Huang H Wei X Sodium alginate coating simultaneously increases the biosafety and immunotherapeutic activity of the cationic mRNA nanovaccine Acta Pharm Sin B 2023 13 3 942 954 10.1016/j.apsb.2022.08.015 36970209
Duan X, Zhang Y, Guo M, Fan N, Chen K, Qin S, Xiao W, Zheng Q, Huang H, Wei X, et al. Sodium alginate coating simultaneously increases the biosafety and immunotherapeutic activity of the cationic mRNA nanovaccine. Acta Pharm Sin B. 2023;13(3):942–54.36970209 10.1016/j.apsb.2022.08.015
80. Pandey P Kim SH Subedi L Mujahid K Kim Y Cho YC Shim JH Kim KT Cho SS Choi JU Oral lymphatic delivery of alpha-galactosylceramide and ovalbumin evokes anti-cancer immunization J Control Release 2023 356 507 524 10.1016/j.jconrel.2023.03.010 36907564
Pandey P, Kim SH, Subedi L, Mujahid K, Kim Y, Cho YC, Shim JH, Kim KT, Cho SS, Choi JU, et al. Oral lymphatic delivery of alpha-galactosylceramide and ovalbumin evokes anti-cancer immunization. J Control Release. 2023;356:507–24.36907564 10.1016/j.jconrel.2023.03.010
81. Teixeira HF Bruxel F Fraga M Schuh RS Zorzi GK Matte U Fattal E Cationic nanoemulsions as nucleic acids delivery systems Int J Pharm 2017 534 1–2 356 367 10.1016/j.ijpharm.2017.10.030 29038065
Teixeira HF, Bruxel F, Fraga M, Schuh RS, Zorzi GK, Matte U, Fattal E. Cationic nanoemulsions as nucleic acids delivery systems. Int J Pharm. 2017;534(1–2):356–67.29038065 10.1016/j.ijpharm.2017.10.030
82. Silva AL Marcelino HR Verissimo LM Araujo IB Agnez-Lima LF do Egito ES: stearylamine-containing cationic nanoemulsion as a promising carrier for gene delivery J Nanosci Nanotechnol 2016 16 2 1339 1345 10.1166/jnn.2016.11671 27433584
Silva AL, Marcelino HR, Verissimo LM, Araujo IB, Agnez-Lima LF. do Egito ES: stearylamine-containing cationic nanoemulsion as a promising carrier for gene delivery. J Nanosci Nanotechnol. 2016;16(2):1339–45.27433584 10.1166/jnn.2016.11671
83. Stokes A Pion J Binazon O Laffont B Bigras M Dubois G Blouin K Young JK Ringenberg MA Ben Abdeljelil N Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats Regul Toxicol Pharmacol 2020 113 104648 10.1016/j.yrtph.2020.104648 32240713
Stokes A, Pion J, Binazon O, Laffont B, Bigras M, Dubois G, Blouin K, Young JK, Ringenberg MA, Ben Abdeljelil N, et al. Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats. Regul Toxicol Pharmacol. 2020;113:104648.32240713 10.1016/j.yrtph.2020.104648
84. Huang J Wang K Wu S Zhang J Chen X Lei S Wu J Men K Duan X Tumor Cell Lysate-Based Multifunctional Nanoparticles Facilitate Enhanced mRNA Delivery and Immune Stimulation for Melanoma Gene Therapy Mol Pharm 2024 21 1 267 282 10.1021/acs.molpharmaceut.3c00826 38079527
Huang J, Wang K, Wu S, Zhang J, Chen X, Lei S, Wu J, Men K, Duan X. Tumor Cell Lysate-Based Multifunctional Nanoparticles Facilitate Enhanced mRNA Delivery and Immune Stimulation for Melanoma Gene Therapy. Mol Pharm. 2024;21(1):267–82.38079527 10.1021/acs.molpharmaceut.3c00826
85. Porosk L Härk HH Arukuusk P Haljasorg U Peterson P Kurrikoff K The development of cell-penetrating peptides for efficient and selective in vivo expression of mRNA in spleen tissue Pharmaceutics 2023 15 3 952 10.3390/pharmaceutics15030952 36986813
Porosk L, Härk HH, Arukuusk P, Haljasorg U, Peterson P, Kurrikoff K. The development of cell-penetrating peptides for efficient and selective in vivo expression of mRNA in spleen tissue. Pharmaceutics. 2023;15(3):952.36986813 10.3390/pharmaceutics15030952
86. Chaudhary N Weissman D Whitehead KA mRNA vaccines for infectious diseases: principles, delivery and clinical translation Nat Rev Drug Discov 2021 20 11 817 838 10.1038/s41573-021-00283-5 34433919
Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021;20(11):817–38.34433919 10.1038/s41573-021-00283-5
87. Mohamad Razif MI Nizar N Zainal Abidin NH Muhammad Ali SN Wan Zarimi WNN Khotib J Susanti D Mohd Jailani MT Taher M Emergence of mRNA vaccines in the management of cancer Expert Rev Vaccines 2023 22 1 629 642 10.1080/14760584.2023.2232450 37401128
Mohamad Razif MI, Nizar N, Zainal Abidin NH, Muhammad Ali SN, Wan Zarimi WNN, Khotib J, Susanti D, Mohd Jailani MT, Taher M. Emergence of mRNA vaccines in the management of cancer. Expert Rev Vaccines. 2023;22(1):629–42.37401128 10.1080/14760584.2023.2232450
88. Qiu Y Man RCH Liao Q Kung KLK Chow MYT Lam JKW Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide J Control Release 2019 314 102 115 10.1016/j.jconrel.2019.10.026 31629037
Qiu Y, Man RCH, Liao Q, Kung KLK, Chow MYT, Lam JKW. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Control Release. 2019;314:102–15.31629037 10.1016/j.jconrel.2019.10.026
89. Khan MM Filipczak N Torchilin VP Cell penetrating peptides: A versatile vector for co-delivery of drug and genes in cancer J Control Release 2021 330 1220 1228 10.1016/j.jconrel.2020.11.028 33248708
Khan MM, Filipczak N, Torchilin VP. Cell penetrating peptides: A versatile vector for co-delivery of drug and genes in cancer. J Control Release. 2021;330:1220–8.33248708 10.1016/j.jconrel.2020.11.028
90. Fotin-Mleczek M Duchardt KM Lorenz C Pfeiffer R Ojkić-Zrna S Probst J Kallen KJ Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity J Immunother 2011 34 1 1 15 10.1097/CJI.0b013e3181f7dbe8 21150709
Fotin-Mleczek M, Duchardt KM, Lorenz C, Pfeiffer R, Ojkić-Zrna S, Probst J, Kallen KJ. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011;34(1):1–15.21150709 10.1097/CJI.0b013e3181f7dbe8
91. Chen Z Meng C Mai J Liu Y Li H Shen H An mRNA vaccine elicits STING-dependent antitumor immune responses Acta Pharm Sin B 2023 13 3 1274 1286 10.1016/j.apsb.2022.11.013 36970194
Chen Z, Meng C, Mai J, Liu Y, Li H, Shen H. An mRNA vaccine elicits STING-dependent antitumor immune responses. Acta Pharm Sin B. 2023;13(3):1274–86.36970194 10.1016/j.apsb.2022.11.013
92. Hasan M Khatun A Kogure K Intradermal delivery of naked mRNA vaccines via Iontophoresis Pharmaceutics 2023 15 12 2678 10.3390/pharmaceutics15122678 38140019
Hasan M, Khatun A, Kogure K. Intradermal delivery of naked mRNA vaccines via Iontophoresis. Pharmaceutics. 2023;15(12):2678.38140019 10.3390/pharmaceutics15122678
93. Stewart MP Langer R Jensen KF Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts Chem Rev 2018 118 16 7409 7531 10.1021/acs.chemrev.7b00678 30052023
Stewart MP, Langer R, Jensen KF. Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts. Chem Rev. 2018;118(16):7409–531.30052023 10.1021/acs.chemrev.7b00678
94. Wang Y Zhang Z Luo J Han X Wei Y Wei X mRNA vaccine: a potential therapeutic strategy Mol Cancer 2021 20 1 33 10.1186/s12943-021-01311-z 33593376
Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021;20(1):33.33593376 10.1186/s12943-021-01311-z
95. Shrestha A Zhu Y Ali A High-fat diet influences dendritic cells and T-Cell infiltration in apical periodontitis in mice J Endod 2024 50 4 506 513.e502 10.1016/j.joen.2024.01.015 38280515
Shrestha A, Zhu Y, Ali A. High-fat diet influences dendritic cells and T-Cell infiltration in apical periodontitis in mice. J Endod. 2024;50(4):506–513.e502.38280515 10.1016/j.joen.2024.01.015
96. Hiasa M Abe M Nakano A Oda A Amou H Kido S Takeuchi K Kagawa K Yata K Hashimoto T GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE) Blood 2009 114 20 4517 4526 10.1182/blood-2009-04-215020 19762488
Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S, Takeuchi K, Kagawa K, Yata K, Hashimoto T, et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood. 2009;114(20):4517–26.19762488 10.1182/blood-2009-04-215020
97. Kranz LM Diken M Haas H Kreiter S Loquai C Reuter KC Meng M Fritz D Vascotto F Hefesha H Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy Nature 2016 534 7607 396 401 10.1038/nature18300 27281205
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534(7607):396–401.27281205 10.1038/nature18300
98. Ho W Gao M Li F Li Z Zhang XQ Xu X Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery Adv Healthc Mater 2021 10 8 e2001812 10.1002/adhm.202001812 33458958
Ho W, Gao M, Li F, Li Z, Zhang XQ, Xu X. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Adv Healthc Mater. 2021;10(8):e2001812.33458958 10.1002/adhm.202001812
99. John R Monpara J Swaminathan S Kalhapure R Chemistry and art of developing lipid nanoparticles for biologics delivery: focus on development and scale-up Pharmaceutics 2024 16 1 131 10.3390/pharmaceutics16010131 38276502
John R, Monpara J, Swaminathan S, Kalhapure R. Chemistry and art of developing lipid nanoparticles for biologics delivery: focus on development and scale-up. Pharmaceutics. 2024;16(1):131.38276502 10.3390/pharmaceutics16010131
100. Xue Y Zhang Y Zhong Y Du S Hou X Li W Li H Wang S Wang C Yan J LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing Nat Commun 2024 15 1 739 10.1038/s41467-024-45094-5 38272900
Xue Y, Zhang Y, Zhong Y, Du S, Hou X, Li W, Li H, Wang S, Wang C, Yan J, et al. LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing. Nat Commun. 2024;15(1):739.38272900 10.1038/s41467-024-45094-5
101. Dehghani-Ghahnaviyeh S Smith M Xia Y Dousis A Grossfield A Sur S Ionizable amino lipids distribution and effects on DSPC/cholesterol membranes: implications for lipid nanoparticle structure J Phys Chem B 2023 127 31 6928 6939 10.1021/acs.jpcb.3c01296 37498794
Dehghani-Ghahnaviyeh S, Smith M, Xia Y, Dousis A, Grossfield A, Sur S. Ionizable amino lipids distribution and effects on DSPC/cholesterol membranes: implications for lipid nanoparticle structure. J Phys Chem B. 2023;127(31):6928–39.37498794 10.1021/acs.jpcb.3c01296
102. Patel SK Billingsley MM Mukalel AJ Thatte AS Hamilton AG Gong N El-Mayta R Safford HC Merolle M Mitchell MJ Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery Theranostics 2024 14 1 1 16 10.7150/thno.89913 38164140
Patel SK, Billingsley MM, Mukalel AJ, Thatte AS, Hamilton AG, Gong N, El-Mayta R, Safford HC, Merolle M, Mitchell MJ. Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery. Theranostics. 2024;14(1):1–16.38164140 10.7150/thno.89913
103. Thelen JL Leite W Urban VS O'Neill HM Grishaev AV Curtis JE Krueger S Castellanos MM Morphological characterization of self-amplifying mRNA lipid nanoparticles ACS Nano 2024 18 2 1464 1476 10.1021/acsnano.3c08014 38175970
Thelen JL, Leite W, Urban VS, O’Neill HM, Grishaev AV, Curtis JE, Krueger S, Castellanos MM. Morphological characterization of self-amplifying mRNA lipid nanoparticles. ACS Nano. 2024;18(2):1464–76.38175970 10.1021/acsnano.3c08014
104. Hassett KJ Higgins J Woods A Levy B Xia Y Hsiao CJ Acosta E Almarsson Ö Moore MJ Brito LA Impact of lipid nanoparticle size on mRNA vaccine immunogenicity J Control Release 2021 335 237 246 10.1016/j.jconrel.2021.05.021 34019945
Hassett KJ, Higgins J, Woods A, Levy B, Xia Y, Hsiao CJ, Acosta E, Almarsson Ö, Moore MJ, Brito LA. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Control Release. 2021;335:237–46.34019945 10.1016/j.jconrel.2021.05.021
105. Chen SP Blakney AK Immune response to the components of lipid nanoparticles for ribonucleic acid therapeutics Curr Opin Biotechnol 2024 85 103049 10.1016/j.copbio.2023.103049 38118363
Chen SP, Blakney AK. Immune response to the components of lipid nanoparticles for ribonucleic acid therapeutics. Curr Opin Biotechnol. 2024;85:103049.38118363 10.1016/j.copbio.2023.103049
106. Wang H Yuan Y Qin L Yue M Xue J Cui Z Zhan X Gai J Zhang X Guan J Tunable rigidity of PLGA shell-lipid core nanoparticles for enhanced pulmonary siRNA delivery in 2D and 3D lung cancer cell models J Control Release 2024 366 746 760 10.1016/j.jconrel.2024.01.029 38237688
Wang H, Yuan Y, Qin L, Yue M, Xue J, Cui Z, Zhan X, Gai J, Zhang X, Guan J, et al. Tunable rigidity of PLGA shell-lipid core nanoparticles for enhanced pulmonary siRNA delivery in 2D and 3D lung cancer cell models. J Control Release. 2024;366:746–60.38237688 10.1016/j.jconrel.2024.01.029
107. Packer M Gyawali D Yerabolu R Schariter J White P A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems Nat Commun 2021 12 1 6777 10.1038/s41467-021-26926-0 34811367
Packer M, Gyawali D, Yerabolu R, Schariter J, White P. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems. Nat Commun. 2021;12(1):6777.34811367 10.1038/s41467-021-26926-0
108. Voicu G Rebleanu D Mocanu CA Tanko G Droc I Uritu CM Pinteala M Manduteanu I Simionescu M Calin M VCAM-1 Targeted lipopolyplexes as vehicles for efficient delivery of shRNA-Runx2 to osteoblast-differentiated valvular interstitial cells; implications in calcific valve disease treatment Int J Mol Sci. 2022 23 7 3824 10.3390/ijms23073824 35409184
Voicu G, Rebleanu D, Mocanu CA, Tanko G, Droc I, Uritu CM, Pinteala M, Manduteanu I, Simionescu M, Calin M. VCAM-1 Targeted lipopolyplexes as vehicles for efficient delivery of shRNA-Runx2 to osteoblast-differentiated valvular interstitial cells; implications in calcific valve disease treatment. Int J Mol Sci. 2022;23(7):3824.35409184 10.3390/ijms23073824
109. Joubert F Munson MJ Sabirsh A England RM Hemmerling M Alexander C Ashford MB Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA J Control Release 2023 356 580 594 10.1016/j.jconrel.2023.03.011 36918085
Joubert F, Munson MJ, Sabirsh A, England RM, Hemmerling M, Alexander C, Ashford MB. Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA. J Control Release. 2023;356:580–94.36918085 10.1016/j.jconrel.2023.03.011
110. Li C Cui X Li Y Guo D He S Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in hepatocellular carcinoma Sci Rep 2023 13 1 8681 10.1038/s41598-023-35796-z 37248280
Li C, Cui X, Li Y, Guo D, He S. Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in hepatocellular carcinoma. Sci Rep. 2023;13(1):8681.37248280 10.1038/s41598-023-35796-z
111. Liu X Huang P Yang R Deng H mRNA cancer vaccines: construction and boosting strategies ACS Nano 2023 17 20 19550 19580 10.1021/acsnano.3c05635 37819640
Liu X, Huang P, Yang R, Deng H. mRNA cancer vaccines: construction and boosting strategies. ACS Nano. 2023;17(20):19550–80.37819640 10.1021/acsnano.3c05635
112. Alvarez-Erviti L Seow Y Yin H Betts C Lakhal S Wood MJ Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 2011 29 4 341 345 10.1038/nbt.1807 21423189
Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–5.21423189 10.1038/nbt.1807
113. Rayamajhi S Wilson S Aryal S DeLong R Biocompatible FePO(4) Nanoparticles: Drug Delivery, RNA Stabilization, and Functional Activity Nanoscale Res Lett 2021 16 1 169 10.1186/s11671-021-03626-8 34837559
Rayamajhi S, Wilson S, Aryal S, DeLong R. Biocompatible FePO(4) Nanoparticles: Drug Delivery, RNA Stabilization, and Functional Activity. Nanoscale Res Lett. 2021;16(1):169.34837559 10.1186/s11671-021-03626-8
114. Wang YS Kumari M Chen GH Hong MH Yuan JP Tsai JL Wu HC mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications J Biomed Sci 2023 30 1 84 10.1186/s12929-023-00977-5 37805495
Wang YS, Kumari M, Chen GH, Hong MH, Yuan JP, Tsai JL, Wu HC. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. J Biomed Sci. 2023;30(1):84.37805495 10.1186/s12929-023-00977-5
115. Bialkowski L van Weijnen A Van der Jeught K Renmans D Daszkiewicz L Heirman C Stangé G Breckpot K Aerts JL Thielemans K Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours Sci Rep 2016 6 22509 10.1038/srep22509 26931556
Bialkowski L, van Weijnen A, Van der Jeught K, Renmans D, Daszkiewicz L, Heirman C, Stangé G, Breckpot K, Aerts JL, Thielemans K. Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Sci Rep. 2016;6:22509.26931556 10.1038/srep22509
116. Sahin U Derhovanessian E Miller M Kloke BP Simon P Löwer M Bukur V Tadmor AD Luxemburger U Schrörs B Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer Nature 2017 547 7662 222 226 10.1038/nature23003 28678784
Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6.28678784 10.1038/nature23003
117. Qin S Tang X Chen Y Chen K Fan N Xiao W Zheng Q Li G Teng Y Wu M mRNA-based therapeutics: powerful and versatile tools to combat diseases Signal Transduct Target Ther 2022 7 1 166 10.1038/s41392-022-01007-w 35597779
Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022;7(1):166.35597779 10.1038/s41392-022-01007-w
118. Giampazolias E Schulz O Lim KHJ Rogers NC Chakravarty P Srinivasan N Gordon O Cardoso A Buck MD Poirier EZ Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity Cell 2021 184 15 4016 4031.e4022 10.1016/j.cell.2021.05.021 34081922
Giampazolias E, Schulz O, Lim KHJ, Rogers NC, Chakravarty P, Srinivasan N, Gordon O, Cardoso A, Buck MD, Poirier EZ, et al. Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell. 2021;184(15):4016–4031.e4022.34081922 10.1016/j.cell.2021.05.021
119. Chen J Ye Z Huang C Qiu M Song D Li Y Xu Q Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response Proc Natl Acad Sci U S A 2022 119 34 e2207841119 10.1073/pnas.2207841119 35969778
Chen J, Ye Z, Huang C, Qiu M, Song D, Li Y, Xu Q. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response. Proc Natl Acad Sci U S A. 2022;119(34):e2207841119.35969778 10.1073/pnas.2207841119
120. van Weverwijk A de Visser KE Mechanisms driving the immunoregulatory function of cancer cells Nat Rev Cancer 2023 23 4 193 215 10.1038/s41568-022-00544-4 36717668
van Weverwijk A, de Visser KE. Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer. 2023;23(4):193–215.36717668 10.1038/s41568-022-00544-4
121. Barmada A Klein J Ramaswamy A Brodsky NN Jaycox JR Sheikha H Jones KM Habet V Campbell M Sumida TS Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis Sci Immunol 2023 8 83 eadh3455 10.1126/sciimmunol.adh3455 37146127
Barmada A, Klein J, Ramaswamy A, Brodsky NN, Jaycox JR, Sheikha H, Jones KM, Habet V, Campbell M, Sumida TS, et al. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis. Sci Immunol. 2023;8(83):eadh3455.37146127 10.1126/sciimmunol.adh3455
122. Heine A Juranek S Brossart P Clinical and immunological effects of mRNA vaccines in malignant diseases Mol Cancer 2021 20 1 52 10.1186/s12943-021-01339-1 33722265
Heine A, Juranek S, Brossart P. Clinical and immunological effects of mRNA vaccines in malignant diseases. Mol Cancer. 2021;20(1):52.33722265 10.1186/s12943-021-01339-1
123. Hsu VW Yuan LC Nuchtern JG Lippincott-Schwartz J Hammerling GJ Klausner RD A recycling pathway between the endoplasmic reticulum and the Golgi apparatus for retention of unassembled MHC class I molecules Nature 1991 352 6334 441 444 10.1038/352441a0 1861723
Hsu VW, Yuan LC, Nuchtern JG, Lippincott-Schwartz J, Hammerling GJ, Klausner RD. A recycling pathway between the endoplasmic reticulum and the Golgi apparatus for retention of unassembled MHC class I molecules. Nature. 1991;352(6334):441–4.1861723 10.1038/352441a0
124. Thwe PM Amiel E The role of nitric oxide in metabolic regulation of Dendritic cell immune function Cancer Lett 2018 412 236 242 10.1016/j.canlet.2017.10.032 29107106
Thwe PM, Amiel E. The role of nitric oxide in metabolic regulation of Dendritic cell immune function. Cancer Lett. 2018;412:236–42.29107106 10.1016/j.canlet.2017.10.032
125. Jia S Kim J Esser-Kahn AP Deak P High-throughput screening identification of novel immunomodulatory combinations for the generation of tolerogenic dendritic cells Front Med (Lausanne) 2023 10 1298424 10.3389/fmed.2023.1298424 38249971
Jia S, Kim J, Esser-Kahn AP, Deak P. High-throughput screening identification of novel immunomodulatory combinations for the generation of tolerogenic dendritic cells. Front Med (Lausanne). 2023;10:1298424.38249971 10.3389/fmed.2023.1298424
126. Li D Zhang Y Li S Zheng B A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice Front Microbiol 2023 14 1145114 10.3389/fmicb.2023.1145114 37025641
Li D, Zhang Y, Li S, Zheng B. A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice. Front Microbiol. 2023;14:1145114.37025641 10.3389/fmicb.2023.1145114
127. Aparici-Herraiz I Sánchez-Sánchez G Batlle C Rehues P López-Serrat M Valverde-Estrella L Lloberas J Celada A IRF1 is required for MDA5 (IFIH1) Induction by IFN-α, LPS, and poly(I:C) in murine macrophages J Innate Immun 2023 15 1 297 316 10.1159/000527008 36380629
Aparici-Herraiz I, Sánchez-Sánchez G, Batlle C, Rehues P, López-Serrat M, Valverde-Estrella L, Lloberas J, Celada A. IRF1 is required for MDA5 (IFIH1) Induction by IFN-α, LPS, and poly(I:C) in murine macrophages. J Innate Immun. 2023;15(1):297–316.36380629 10.1159/000527008
128. Xu G Peng H Yao R Yang Y Li B TFEB and TFE3 cooperate in regulating inorganic arsenic-induced autophagy-lysosome impairment and immuno-dysfunction in primary dendritic cells Cell Biol Toxicol 2024 40 1 4 10.1007/s10565-024-09841-0 38267572
Xu G, Peng H, Yao R, Yang Y, Li B. TFEB and TFE3 cooperate in regulating inorganic arsenic-induced autophagy-lysosome impairment and immuno-dysfunction in primary dendritic cells. Cell Biol Toxicol. 2024;40(1):4.38267572 10.1007/s10565-024-09841-0
129. Wolf AJ Reyes CN Liang W Becker C Shimada K Wheeler ML Cho HC Popescu NI Coggeshall KM Arditi M Hexokinase Is an innate immune receptor for the detection of bacterial peptidoglycan Cell 2016 166 3 624 636 10.1016/j.cell.2016.05.076 27374331
Wolf AJ, Reyes CN, Liang W, Becker C, Shimada K, Wheeler ML, Cho HC, Popescu NI, Coggeshall KM, Arditi M, et al. Hexokinase Is an innate immune receptor for the detection of bacterial peptidoglycan. Cell. 2016;166(3):624–36.27374331 10.1016/j.cell.2016.05.076
130. Saadh MJ Rasulova I Khalil M Farahim F Sârbu I Ciongradi CI Omar TM Alhili A Jawad MJ Hani T Natural killer cell-mediated immune surveillance in cancer: role of tumor microenvironment Pathol Res Pract 2024 254 155120 10.1016/j.prp.2024.155120 38280274
Saadh MJ, Rasulova I, Khalil M, Farahim F, Sârbu I, Ciongradi CI, Omar TM, Alhili A, Jawad MJ, Hani T, et al. Natural killer cell-mediated immune surveillance in cancer: role of tumor microenvironment. Pathol Res Pract. 2024;254:155120.38280274 10.1016/j.prp.2024.155120
131. Zhao D Liu X Shan Y Li J Cui W Wang J Jiang J Xie Q Zhang C Duan C Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma Comput Struct Biotechnol J 2022 20 5001 5013 10.1016/j.csbj.2022.08.066 36187916
Zhao D, Liu X, Shan Y, Li J, Cui W, Wang J, Jiang J, Xie Q, Zhang C, Duan C. Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma. Comput Struct Biotechnol J. 2022;20:5001–13.36187916 10.1016/j.csbj.2022.08.066
132. Sadeghi Rad H Monkman J Warkiani ME Ladwa R O'Byrne K Rezaei N Kulasinghe A Understanding the tumor microenvironment for effective immunotherapy Med Res Rev 2021 41 3 1474 1498 10.1002/med.21765 33277742
Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O’Byrne K, Rezaei N, Kulasinghe A. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41(3):1474–98.33277742 10.1002/med.21765
133. Xiao Y Yu D Tumor microenvironment as a therapeutic target in cancer Pharmacol Ther 2021 221 107753 10.1016/j.pharmthera.2020.107753 33259885
Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.33259885 10.1016/j.pharmthera.2020.107753
134. López de Andrés J Griñán-Lisón C Jiménez G Marchal JA Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment J Hematol Oncol. 2020 13 1 136 10.1186/s13045-020-00966-3 33059744
López de Andrés J, Griñán-Lisón C, Jiménez G, Marchal JA. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J Hematol Oncol. 2020;13(1):136.33059744 10.1186/s13045-020-00966-3
135. Zhu KL Su F Yang JR Xiao RW Wu RY Cao MY Ling XL Zhang T TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress Mol Biol Rep 2024 51 1 205 10.1007/s11033-023-09097-7 38270700
Zhu KL, Su F, Yang JR, Xiao RW, Wu RY, Cao MY, Ling XL, Zhang T. TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress. Mol Biol Rep. 2024;51(1):205.38270700 10.1007/s11033-023-09097-7
136. Hotz C Wagenaar TR Gieseke F Bangari DS Callahan M Cao H Diekmann J Diken M Grunwitz C Hebert A Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models Sci Transl Med 2021 13 610 eabc7804 10.1126/scitranslmed.abc7804 34516826
Hotz C, Wagenaar TR, Gieseke F, Bangari DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021;13(610):eabc7804.34516826 10.1126/scitranslmed.abc7804
137. Tombácz I Laczkó D Shahnawaz H Muramatsu H Natesan A Yadegari A Papp TE Alameh MG Shuvaev V Mui BL Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs Mol Ther 2021 29 11 3293 3304 10.1016/j.ymthe.2021.06.004 34091054
Tombácz I, Laczkó D, Shahnawaz H, Muramatsu H, Natesan A, Yadegari A, Papp TE, Alameh MG, Shuvaev V, Mui BL, et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol Ther. 2021;29(11):3293–304.34091054 10.1016/j.ymthe.2021.06.004
138. Peña-Romero AC Orenes-Piñero E Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers Cancers (Basel) 2022 14 7 1681 10.3390/cancers14071681 35406451
Peña-Romero AC, Orenes-Piñero E. Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers. Cancers (Basel). 2022;14(7):1681.35406451 10.3390/cancers14071681
139. Kiousi E Lyraraki V Mardiki GL Stachika N Damianou AK Malainou CP Syrigos N Gomatou G Kotteas E Progress and challenges of messenger RNA vaccines in the therapeutics of NSCLC Cancers (Basel) 2023 15 23 5589 10.3390/cancers15235589 38067293
Kiousi E, Lyraraki V, Mardiki GL, Stachika N, Damianou AK, Malainou CP, Syrigos N, Gomatou G, Kotteas E. Progress and challenges of messenger RNA vaccines in the therapeutics of NSCLC. Cancers (Basel). 2023;15(23):5589.38067293 10.3390/cancers15235589
140. Mudd PA Minervina AA Pogorelyy MV Turner JS Kim W Kalaidina E Petersen J Schmitz AJ Lei T Haile A SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans Cell 2022 185 4 603 613.e615 10.1016/j.cell.2021.12.026 35026152
Mudd PA, Minervina AA, Pogorelyy MV, Turner JS, Kim W, Kalaidina E, Petersen J, Schmitz AJ, Lei T, Haile A, et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell. 2022;185(4):603–613.e615.35026152 10.1016/j.cell.2021.12.026
141. Zhang H You X Wang X Cui L Wang Z Xu F Li M Yang Z Liu J Huang P Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling Proc Natl Acad Sci U S A. 2021 118 6 e2005191118 10.1073/pnas.2005191118 33547233
Zhang H, You X, Wang X, Cui L, Wang Z, Xu F, Li M, Yang Z, Liu J, Huang P, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci U S A. 2021;118(6):e2005191118.33547233 10.1073/pnas.2005191118
142. Luo W Adamska JZ Li C Verma R Liu Q Hagan T Wimmers F Gupta S Feng Y Jiang W SREBP signaling is essential for effective B cell responses Nat Immunol 2023 24 2 337 348 10.1038/s41590-022-01376-y 36577930
Luo W, Adamska JZ, Li C, Verma R, Liu Q, Hagan T, Wimmers F, Gupta S, Feng Y, Jiang W, et al. SREBP signaling is essential for effective B cell responses. Nat Immunol. 2023;24(2):337–48.36577930 10.1038/s41590-022-01376-y
143. Rojas LA Sethna Z Soares KC Olcese C Pang N Patterson E Lihm J Ceglia N Guasp P Chu A Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer Nature 2023 618 7963 144 150 10.1038/s41586-023-06063-y 37165196
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–50.37165196 10.1038/s41586-023-06063-y
144. Topalian SL Taube JM Anders RA Pardoll DM Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy Nat Rev Cancer 2016 16 5 275 287 10.1038/nrc.2016.36 27079802
Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–87.27079802 10.1038/nrc.2016.36
145. Barbier AJ Jiang AY Zhang P Wooster R Anderson DG The clinical progress of mRNA vaccines and immunotherapies Nat Biotechnol 2022 40 6 840 854 10.1038/s41587-022-01294-2 35534554
Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG. The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol. 2022;40(6):840–54.35534554 10.1038/s41587-022-01294-2
146. Ma S Li X Mai Y Guo J Zuo W Yang J Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA/mRNA tumor vaccine Acta Biomater 2023 169 489 499 10.1016/j.actbio.2023.07.059 37536492
Ma S, Li X, Mai Y, Guo J, Zuo W, Yang J. Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA/mRNA tumor vaccine. Acta Biomater. 2023;169:489–99.37536492 10.1016/j.actbio.2023.07.059
147. Takata K Chong LC Ennishi D Aoki T Li MY Thakur A Healy S Viganò E Dao T Kwon D Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma J Clin Invest. 2022 132 10 e145343 10.1172/JCI145343 35380993
Takata K, Chong LC, Ennishi D, Aoki T, Li MY, Thakur A, Healy S, Viganò E, Dao T, Kwon D, et al. Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. J Clin Invest. 2022;132(10):e145343.35380993 10.1172/JCI145343
148. Bhagat A Lyerly HK Morse MA Hartman ZC CEA vaccines hum vaccin immunother 2023 19 3 2291857 10.1080/21645515.2023.2291857 38087989
Bhagat A, Lyerly HK, Morse MA, Hartman ZC. CEA vaccines hum vaccin immunother. 2023;19(3):2291857.38087989 10.1080/21645515.2023.2291857
149. Lezcano C Jungbluth AA Busam KJ PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions Surg Pathol Clin 2021 14 2 165 175 10.1016/j.path.2021.01.001 34023098
Lezcano C, Jungbluth AA, Busam KJ. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions. Surg Pathol Clin. 2021;14(2):165–75.34023098 10.1016/j.path.2021.01.001
150. Smith SM Iwenofu OH NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis Chin Clin Oncol 2018 7 4 44 10.21037/cco.2018.08.11 30173534
Smith SM, Iwenofu OH. NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis. Chin Clin Oncol. 2018;7(4):44.30173534 10.21037/cco.2018.08.11
151. Fortner RT Damms-Machado A Kaaks R Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection Gynecol Oncol 2017 147 2 465 480 10.1016/j.ygyno.2017.07.138 28800944
Fortner RT, Damms-Machado A, Kaaks R. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection. Gynecol Oncol. 2017;147(2):465–80.28800944 10.1016/j.ygyno.2017.07.138
152. Xu S Yang K Li R Zhang L mRNA Vaccine era-mechanisms, drug platform and clinical prospection Int J Mol Sci 2020 21 18 6582 10.3390/ijms21186582 32916818
Xu S, Yang K, Li R, Zhang L. mRNA Vaccine era-mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21(18):6582.32916818 10.3390/ijms21186582
153. Liu C Shi Q Huang X Koo S Kong N Tao W mRNA-based cancer therapeutics Nat Rev Cancer 2023 23 8 526 543 10.1038/s41568-023-00586-2 37311817
Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. mRNA-based cancer therapeutics. Nat Rev Cancer. 2023;23(8):526–43.37311817 10.1038/s41568-023-00586-2
154. Miao L Zhang Y Huang L mRNA vaccine for cancer immunotherapy Mol Cancer 2021 20 1 41 10.1186/s12943-021-01335-5 33632261
Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41.33632261 10.1186/s12943-021-01335-5
155. Wells DK van Buuren MM Dang KK Hubbard-Lucey VM Sheehan KCF Campbell KM Lamb A Ward JP Sidney J Blazquez AB Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction Cell 2020 183 3 818 834.e813 10.1016/j.cell.2020.09.015 33038342
Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020;183(3):818–834.e813.33038342 10.1016/j.cell.2020.09.015
156. Esprit A de Mey W Bahadur Shahi R Thielemans K Franceschini L Breckpot K Neo-antigen mRNA vaccines Vaccines (Basel) 2020 8 4 776 10.3390/vaccines8040776 33353155
Esprit A, de Mey W, Bahadur Shahi R, Thielemans K, Franceschini L, Breckpot K. Neo-antigen mRNA vaccines. Vaccines (Basel). 2020;8(4):776.33353155 10.3390/vaccines8040776
157. Akram N Imran M Noreen M Ahmed F Atif M Fatima Z Bilal Waqar A Oncogenic Role of Tumor Viruses in Humans Viral Immunol 2017 30 1 20 27 10.1089/vim.2016.0109 27830995
Akram N, Imran M, Noreen M, Ahmed F, Atif M, Fatima Z, Bilal Waqar A. Oncogenic Role of Tumor Viruses in Humans. Viral Immunol. 2017;30(1):20–7.27830995 10.1089/vim.2016.0109
158. Hassan STS Tumor viruses and their associated cancers: remain on the track with the latest advances Viruses 2022 14 2 262 10.3390/v14020262 35215856
Hassan STS. Tumor viruses and their associated cancers: remain on the track with the latest advances. Viruses. 2022;14(2):262.35215856 10.3390/v14020262
159. Zhou K Yuzhakov O Behloul N Wang D Bhagat L Chu D Zhang X Cheng X Fan L Huang X HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions Front Immunol 2023 14 1213285 10.3389/fimmu.2023.1213285 37503351
Zhou K, Yuzhakov O, Behloul N, Wang D, Bhagat L, Chu D, Zhang X, Cheng X, Fan L, Huang X, et al. HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions. Front Immunol. 2023;14:1213285.37503351 10.3389/fimmu.2023.1213285
160. Jiang Y Han Q Zhao H Zhang J The Mechanisms of HBV-Induced Hepatocellular Carcinoma J Hepatocell Carcinoma 2021 8 435 450 10.2147/JHC.S307962 34046368
Jiang Y, Han Q, Zhao H, Zhang J. The Mechanisms of HBV-Induced Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:435–50.34046368 10.2147/JHC.S307962
161. Zhao H Shao X Yu Y Huang L Amor NP Guo K Weng C Zhao W Yang A Hu J A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression NPJ Vaccines 2024 9 1 22 10.1038/s41541-024-00813-3 38310094
Zhao H, Shao X, Yu Y, Huang L, Amor NP, Guo K, Weng C, Zhao W, Yang A, Hu J, et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. NPJ Vaccines. 2024;9(1):22.38310094 10.1038/s41541-024-00813-3
162. Haynes BF Wiehe K Borrow P Saunders KO Korber B Wagh K McMichael AJ Kelsoe G Hahn BH Alt F Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies Nat Rev Immunol 2023 23 3 142 158 10.1038/s41577-022-00753-w 35962033
Haynes BF, Wiehe K, Borrow P, Saunders KO, Korber B, Wagh K, McMichael AJ, Kelsoe G, Hahn BH, Alt F, et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol. 2023;23(3):142–58.35962033 10.1038/s41577-022-00753-w
163. Xie Z Lin YC Steichen JM Ozorowski G Kratochvil S Ray R Torres JL Liguori A Kalyuzhniy O Wang X mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies Science 2024 384 6697 eadk0582 10.1126/science.adk0582 38753770
Xie Z, Lin YC, Steichen JM, Ozorowski G, Kratochvil S, Ray R, Torres JL, Liguori A, Kalyuzhniy O, Wang X, et al. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies. Science. 2024;384(6697):eadk0582.38753770 10.1126/science.adk0582
164. Coffman RL Sher A Seder RA Vaccine adjuvants: putting innate immunity to work Immunity 2010 33 4 492 503 10.1016/j.immuni.2010.10.002 21029960
Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.21029960 10.1016/j.immuni.2010.10.002
165. Karikó K Buckstein M Ni H Weissman D Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA Immunity 2005 23 2 165 175 10.1016/j.immuni.2005.06.008 16111635
Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–75.16111635 10.1016/j.immuni.2005.06.008
166. Uchida S Yoshinaga N Yanagihara K Yuba E Kataoka K Itaka K Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination Biomaterials 2018 150 162 170 10.1016/j.biomaterials.2017.09.033 29031816
Uchida S, Yoshinaga N, Yanagihara K, Yuba E, Kataoka K, Itaka K. Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination. Biomaterials. 2018;150:162–70.29031816 10.1016/j.biomaterials.2017.09.033
167. Tockary TA Abbasi S Matsui-Masai M Hayashi A Yoshinaga N Boonstra E Wang Z Fukushima S Kataoka K Uchida S Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment Proc Natl Acad Sci U S A 2023 120 29 e2214320120 10.1073/pnas.2214320120 37428918
Tockary TA, Abbasi S, Matsui-Masai M, Hayashi A, Yoshinaga N, Boonstra E, Wang Z, Fukushima S, Kataoka K, Uchida S. Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment. Proc Natl Acad Sci U S A. 2023;120(29):e2214320120.37428918 10.1073/pnas.2214320120
168. Pulendran B S Arunachalam P O'Hagan DT Emerging concepts in the science of vaccine adjuvants Nat Rev Drug Discov 2021 20 6 454 475 10.1038/s41573-021-00163-y 33824489
Pulendran B, S Arunachalam P, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;20(6):454–75.33824489 10.1038/s41573-021-00163-y
169. Li C Lee A Grigoryan L Arunachalam PS Scott MKD Trisal M Wimmers F Sanyal M Weidenbacher PA Feng Y Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine Nat Immunol 2022 23 4 543 555 10.1038/s41590-022-01163-9 35288714
Li C, Lee A, Grigoryan L, Arunachalam PS, Scott MKD, Trisal M, Wimmers F, Sanyal M, Weidenbacher PA, Feng Y, et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022;23(4):543–55.35288714 10.1038/s41590-022-01163-9
170. Galon J Bruni D Approaches to treat immune hot, altered and cold tumours with combination immunotherapies Nat Rev Drug Discov 2019 18 3 197 218 10.1038/s41573-018-0007-y 30610226
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.30610226 10.1038/s41573-018-0007-y
171. Yim HJ Jean T Ong PY Recent advances in immunomodulators for atopic dermatitis Curr Opin Pediatr 2023 35 6 671 679 10.1097/MOP.0000000000001279 37522635
Yim HJ, Jean T, Ong PY. Recent advances in immunomodulators for atopic dermatitis. Curr Opin Pediatr. 2023;35(6):671–9.37522635 10.1097/MOP.0000000000001279
172. Demaria O Cornen S Daëron M Morel Y Medzhitov R Vivier E Harnessing innate immunity in cancer therapy Nature 2019 574 7776 45 56 10.1038/s41586-019-1593-5 31578484
Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56.31578484 10.1038/s41586-019-1593-5
173. Aricò E Castiello L Capone I Gabriele L Belardelli F Type I interferons and cancer: an evolving story demanding novel clinical applications Cancers (Basel) 2019 11 12 1943 10.3390/cancers11121943 31817234
Aricò E, Castiello L, Capone I, Gabriele L, Belardelli F. Type I interferons and cancer: an evolving story demanding novel clinical applications. Cancers (Basel). 2019;11(12):1943.31817234 10.3390/cancers11121943
174. Propper DJ Balkwill FR Harnessing cytokines and chemokines for cancer therapy Nat Rev Clin Oncol 2022 19 4 237 253 10.1038/s41571-021-00588-9 34997230
Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022;19(4):237–53.34997230 10.1038/s41571-021-00588-9
175. Lai I Swaminathan S Baylot V Mosley A Dhanasekaran R Gabay M Felsher DW Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma J Immunother Cancer 2018 6 1 125 10.1186/s40425-018-0431-x 30458889
Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M, Felsher DW. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J Immunother Cancer. 2018;6(1):125.30458889 10.1186/s40425-018-0431-x
176. Liu JQ Zhang C Zhang X Yan J Zeng C Talebian F Lynch K Zhao W Hou X Du S Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy J Control Release 2022 345 306 313 10.1016/j.jconrel.2022.03.021 35301053
Liu JQ, Zhang C, Zhang X, Yan J, Zeng C, Talebian F, Lynch K, Zhao W, Hou X, Du S, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release. 2022;345:306–13.35301053 10.1016/j.jconrel.2022.03.021
177. Haabeth OAW Blake TR McKinlay CJ Tveita AA Sallets A Waymouth RM Wender PA Levy R Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity Cancer Res 2019 79 7 1624 1634 10.1158/0008-5472.CAN-18-2867 30692215
Haabeth OAW, Blake TR, McKinlay CJ, Tveita AA, Sallets A, Waymouth RM, Wender PA, Levy R. Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity. Cancer Res. 2019;79(7):1624–34.30692215 10.1158/0008-5472.CAN-18-2867
178. Mai D June CH Sheppard NC In vivo gene immunotherapy for cancer Sci Transl Med 2022 14 670 eabo3603 10.1126/scitranslmed.abo3603 36350990
Mai D, June CH, Sheppard NC. In vivo gene immunotherapy for cancer. Sci Transl Med. 2022;14(670):eabo3603.36350990 10.1126/scitranslmed.abo3603
179. Sun H Zhang Y Wang G Yang W Xu Y mRNA-based therapeutics in cancer treatment Pharmaceutics 2023 15 2 622 10.3390/pharmaceutics15020622 36839944
Sun H, Zhang Y, Wang G, Yang W, Xu Y. mRNA-based therapeutics in cancer treatment. Pharmaceutics. 2023;15(2):622.36839944 10.3390/pharmaceutics15020622
180. Strebhardt K Ullrich A Paul Ehrlich's magic bullet concept: 100 years of progress Nat Rev Cancer 2008 8 6 473 480 10.1038/nrc2394 18469827
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–80.18469827 10.1038/nrc2394
181. Labrijn AF Janmaat ML Reichert JM Parren P Bispecific antibodies: a mechanistic review of the pipeline Nat Rev Drug Discov 2019 18 8 585 608 10.1038/s41573-019-0028-1 31175342
Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608.31175342 10.1038/s41573-019-0028-1
182. Thran M Mukherjee J Pönisch M Fiedler K Thess A Mui BL Hope MJ Tam YK Horscroft N Heidenreich R mRNA mediates passive vaccination against infectious agents, toxins, and tumors EMBO Mol Med 2017 9 10 1434 1447 10.15252/emmm.201707678 28794134
Thran M, Mukherjee J, Pönisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017;9(10):1434–47.28794134 10.15252/emmm.201707678
183. Rybakova Y Kowalski PS Huang Y Gonzalez JT Heartlein MW DeRosa F Delcassian D Anderson DG mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo Mol Ther 2019 27 8 1415 1423 10.1016/j.ymthe.2019.05.012 31160223
Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, Delcassian D, Anderson DG. mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo. Mol Ther. 2019;27(8):1415–23.31160223 10.1016/j.ymthe.2019.05.012
184. Wang Y Tiruthani K Li S Hu M Zhong G Tang Y Roy S Zhang L Tan J Liao C mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies Adv Mater 2021 33 23 e2007603 10.1002/adma.202007603 33945178
Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, Roy S, Zhang L, Tan J, Liao C, et al. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies. Adv Mater. 2021;33(23):e2007603.33945178 10.1002/adma.202007603
185. Klinger M Benjamin J Kischel R Stienen S Zugmaier G Harnessing T cells to fight cancer with BiTE® antibody constructs–past developments and future directions Immunol Rev 2016 270 1 193 208 10.1111/imr.12393 26864113
Klinger M, Benjamin J, Kischel R, Stienen S, Zugmaier G. Harnessing T cells to fight cancer with BiTE® antibody constructs–past developments and future directions. Immunol Rev. 2016;270(1):193–208.26864113 10.1111/imr.12393
186. Stadler CR Bähr-Mahmud H Celik L Hebich B Roth AS Roth RP Karikó K Türeci Ö Sahin U Elimination of large tumors in mice by mRNA-encoded bispecific antibodies Nat Med 2017 23 7 815 817 10.1038/nm.4356 28604701
Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017;23(7):815–7.28604701 10.1038/nm.4356
187. Alameh MG Tombácz I Bettini E Lederer K Sittplangkoon C Wilmore JR Gaudette BT Soliman OY Pine M Hicks P Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses Immunity 2021 54 12 2877 2892.e2877 10.1016/j.immuni.2021.11.001 34852217
Alameh MG, Tombácz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore JR, Gaudette BT, Soliman OY, Pine M, Hicks P, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877–2892.e2877.34852217 10.1016/j.immuni.2021.11.001
188. Han X Alameh MG Butowska K Knox JJ Lundgreen K Ghattas M Gong N Xue L Xu Y Lavertu M Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines Nat Nanotechnol 2023 18 9 1105 1114 10.1038/s41565-023-01404-4 37365276
Han X, Alameh MG, Butowska K, Knox JJ, Lundgreen K, Ghattas M, Gong N, Xue L, Xu Y, Lavertu M, et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat Nanotechnol. 2023;18(9):1105–14.37365276 10.1038/s41565-023-01404-4
189. Zhang Y Yan J Hou X Wang C Kang DD Xue Y Du S Deng B McComb DW Liu SL STING agonist-derived LNP-mRNA vaccine enhances protective immunity against SARS-CoV-2 Nano Lett 2023 23 7 2593 2600 10.1021/acs.nanolett.2c04883 36942873
Zhang Y, Yan J, Hou X, Wang C, Kang DD, Xue Y, Du S, Deng B, McComb DW, Liu SL, et al. STING agonist-derived LNP-mRNA vaccine enhances protective immunity against SARS-CoV-2. Nano Lett. 2023;23(7):2593–600.36942873 10.1021/acs.nanolett.2c04883
190. Li W Li Y Li J Meng J Jiang Z Yang C Wen Y Liu S Cheng X Mi S All-Trans-retinoic acid-adjuvanted mRNA vaccine induces mucosal anti-tumor immune responses for treating colorectal cancer Adv Sci (Weinh) 2024 11 22 e2309770 10.1002/advs.202309770 38528670
Li W, Li Y, Li J, Meng J, Jiang Z, Yang C, Wen Y, Liu S, Cheng X, Mi S, et al. All-Trans-retinoic acid-adjuvanted mRNA vaccine induces mucosal anti-tumor immune responses for treating colorectal cancer. Adv Sci (Weinh). 2024;11(22):e2309770.38528670 10.1002/advs.202309770
191. Tahtinen S Tong AJ Himmels P Oh J Paler-Martinez A Kim L Wichner S Oei Y McCarron MJ Freund EC IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines Nat Immunol 2022 23 4 532 542 10.1038/s41590-022-01160-y 35332327
Tahtinen S, Tong AJ, Himmels P, Oh J, Paler-Martinez A, Kim L, Wichner S, Oei Y, McCarron MJ, Freund EC, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23(4):532–42.35332327 10.1038/s41590-022-01160-y
192. Inozume T Adoptive cell transfer therapy for melanoma Exp Dermatol 2023 32 3 250 255 10.1111/exd.14707 36382355
Inozume T. Adoptive cell transfer therapy for melanoma. Exp Dermatol. 2023;32(3):250–5.36382355 10.1111/exd.14707
193. Guedan S Ruella M June CH Emerging Cellular Therapies for Cancer Annu Rev Immunol 2019 37 145 171 10.1146/annurev-immunol-042718-041407 30526160
Guedan S, Ruella M, June CH. Emerging Cellular Therapies for Cancer. Annu Rev Immunol. 2019;37:145–71.30526160 10.1146/annurev-immunol-042718-041407
194. Sterner RC Sterner RM CAR-T cell therapy: current limitations and potential strategies Blood Cancer J 2021 11 4 69 10.1038/s41408-021-00459-7 33824268
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.33824268 10.1038/s41408-021-00459-7
195. Yang D Duan Z Yuan P Ding C Dai X Chen G Wu D How does TCR-T cell therapy exhibit a superior anti-tumor efficacy Biochem Biophys Res Commun 2023 687 149209 10.1016/j.bbrc.2023.149209 37944471
Yang D, Duan Z, Yuan P, Ding C, Dai X, Chen G, Wu D. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy. Biochem Biophys Res Commun. 2023;687:149209.37944471 10.1016/j.bbrc.2023.149209
196. Baulu E Gardet C Chuvin N Depil S TCR-engineered T cell therapy in solid tumors: State of the art and perspectives Sci Adv. 2023 9 7 eadf3700 10.1126/sciadv.adf3700 36791198
Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.36791198 10.1126/sciadv.adf3700
197. Pang Z Lu MM Zhang Y Gao Y Bai JJ Gu JY Xie L Wu WZ Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges Biomark Res 2023 11 1 104 10.1186/s40364-023-00534-0 38037114
Pang Z, Lu MM, Zhang Y, Gao Y, Bai JJ, Gu JY, Xie L, Wu WZ. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11(1):104.38037114 10.1186/s40364-023-00534-0
198. Wei L Dong C Zhu W Wang BZ mRNA vaccine nanoplatforms and innate immunity Viruses 2024 16 1 120 10.3390/v16010120 38257820
Wei L, Dong C, Zhu W, Wang BZ. mRNA vaccine nanoplatforms and innate immunity. Viruses. 2024;16(1):120.38257820 10.3390/v16010120
199. Yang F Zheng X Koh S Lu J Cheng J Li P Du C Chen Y Chen X Yang L Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial Hepatol Int 2023 17 4 850 859 10.1007/s12072-023-10524-x 37067675
Yang F, Zheng X, Koh S, Lu J, Cheng J, Li P, Du C, Chen Y, Chen X, Yang L, et al. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial. Hepatol Int. 2023;17(4):850–9.37067675 10.1007/s12072-023-10524-x
200. Shen L Yang J Zuo C Xu J Ma L He Q Zhou X Ding X Wei L Jiang S Circular mRNA-based TCR-T offers a safe and effective therapeutic strategy for treatment of cytomegalovirus infection Mol Ther 2024 32 1 168 184 10.1016/j.ymthe.2023.11.017 37974400
Shen L, Yang J, Zuo C, Xu J, Ma L, He Q, Zhou X, Ding X, Wei L, Jiang S, et al. Circular mRNA-based TCR-T offers a safe and effective therapeutic strategy for treatment of cytomegalovirus infection. Mol Ther. 2024;32(1):168–84.37974400 10.1016/j.ymthe.2023.11.017
201. Nakamura N Jo T Arai Y Kitawaki T Nishikori M Mizumoto C Kanda J Yamashita K Nagao M Takaori-Kondo A Clinical impact of cytokine release syndrome on prolonged hematotoxicity after chimeric antigen receptor T cell therapy: KyoTox A-score, a novel prediction model Transplant Cell Ther 2024 30 4 404 414 10.1016/j.jtct.2024.01.073 38281589
Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, Kanda J, Yamashita K, Nagao M, Takaori-Kondo A. Clinical impact of cytokine release syndrome on prolonged hematotoxicity after chimeric antigen receptor T cell therapy: KyoTox A-score, a novel prediction model. Transplant Cell Ther. 2024;30(4):404–14.38281589 10.1016/j.jtct.2024.01.073
202. Tchou J Zhao Y Levine BL Zhang PJ Davis MM Melenhorst JJ Kulikovskaya I Brennan AL Liu X Lacey SF Safety and efficacy of intratumoral injections of Chimeric Antigen Receptor (CAR) T Cells in metastatic breast cancer Cancer Immunol Res 2017 5 12 1152 1161 10.1158/2326-6066.CIR-17-0189 29109077
Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I, Brennan AL, Liu X, Lacey SF, et al. Safety and efficacy of intratumoral injections of Chimeric Antigen Receptor (CAR) T Cells in metastatic breast cancer. Cancer Immunol Res. 2017;5(12):1152–61.29109077 10.1158/2326-6066.CIR-17-0189
203. Beatty GL O'Hara MH Lacey SF Torigian DA Nazimuddin F Chen F Kulikovskaya IM Soulen MC McGarvey M Nelson AM Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial Gastroenterology 2018 155 1 29 32 10.1053/j.gastro.2018.03.029 29567081
Beatty GL, O’Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29–32.29567081 10.1053/j.gastro.2018.03.029
204. Zhang F Parayath NN Ene CI Stephan SB Koehne AL Coon ME Holland EC Stephan MT Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers Nat Commun 2019 10 1 3974 10.1038/s41467-019-11911-5 31481662
Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, Holland EC, Stephan MT. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun. 2019;10(1):3974.31481662 10.1038/s41467-019-11911-5
205. Han R Wang Y Lu L Sensitizing the efficiency of ICIs by neoantigen mRNA vaccines for HCC treatment Pharmaceutics 2023 16 1 59 10.3390/pharmaceutics16010059 38258070
Han R, Wang Y, Lu L. Sensitizing the efficiency of ICIs by neoantigen mRNA vaccines for HCC treatment. Pharmaceutics. 2023;16(1):59.38258070 10.3390/pharmaceutics16010059
206. Sahin U Oehm P Derhovanessian E Jabulowsky RA Vormehr M Gold M Maurus D Schwarck-Kokarakis D Kuhn AN Omokoko T An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma Nature 2020 585 7823 107 112 10.1038/s41586-020-2537-9 32728218
Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–12.32728218 10.1038/s41586-020-2537-9
207. Poh A. mRNA Vaccine Slows Melanoma Recurrence. Cancer Discov. 2023;13(6):1278.
208. Liu L Wang Y Miao L Liu Q Musetti S Li J Huang L Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer Mol Ther 2018 26 1 45 55 10.1016/j.ymthe.2017.10.020 29258739
Liu L, Wang Y, Miao L, Liu Q, Musetti S, Li J, Huang L. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Mol Ther. 2018;26(1):45–55.29258739 10.1016/j.ymthe.2017.10.020
209. Wei T Li Y Li B Xie Q Huang Y Wu Z Chen H Meng Y Liang L Wang M Plasmid co-expressing siRNA-PD-1 and Endostatin carried by attenuated Salmonella enhanced the anti-melanoma effect via inhibiting the expression of PD-1 and VEGF on tumor-bearing mice Int Immunopharmacol 2024 127 111362 10.1016/j.intimp.2023.111362 38103411
Wei T, Li Y, Li B, Xie Q, Huang Y, Wu Z, Chen H, Meng Y, Liang L, Wang M, et al. Plasmid co-expressing siRNA-PD-1 and Endostatin carried by attenuated Salmonella enhanced the anti-melanoma effect via inhibiting the expression of PD-1 and VEGF on tumor-bearing mice. Int Immunopharmacol. 2024;127:111362.38103411 10.1016/j.intimp.2023.111362
210. Wan PK Ryan AJ Seymour LW Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus Mol Ther 2021 29 5 1668 1682 10.1016/j.ymthe.2021.04.015 33845199
Wan PK, Ryan AJ, Seymour LW. Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Mol Ther. 2021;29(5):1668–82.33845199 10.1016/j.ymthe.2021.04.015
211. Gao L Wu ZX Assaraf YG Chen ZS Wang L Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function Drug Resist Updat 2021 57 100770 10.1016/j.drup.2021.100770 34175687
Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021;57:100770.34175687 10.1016/j.drup.2021.100770
212. Vogelstein B Papadopoulos N Velculescu VE Zhou S Diaz LA Jr Kinzler KW Cancer genome landscapes Science 2013 339 6127 1546 1558 10.1126/science.1235122 23539594
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546–58.23539594 10.1126/science.1235122
213. Islam MA Xu Y Tao W Ubellacker JM Lim M Aum D Lee GY Zhou K Zope H Yu M Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA Nat Biomed Eng 2018 2 11 850 864 10.1038/s41551-018-0284-0 31015614
Islam MA, Xu Y, Tao W, Ubellacker JM, Lim M, Aum D, Lee GY, Zhou K, Zope H, Yu M, et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2018;2(11):850–64.31015614 10.1038/s41551-018-0284-0
214. Lin YX Wang Y Ding J Jiang A Wang J Yu M Blake S Liu S Bieberich CJ Farokhzad OC Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models Sci Transl Med 2021 13 599 eaba9772 10.1126/scitranslmed.aba9772 34162754
Lin YX, Wang Y, Ding J, Jiang A, Wang J, Yu M, Blake S, Liu S, Bieberich CJ, Farokhzad OC, et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med. 2021;13(599):eaba9772.34162754 10.1126/scitranslmed.aba9772
215. Rohner E Yang R Foo KS Goedel A Chien KR Unlocking the promise of mRNA therapeutics Nat Biotechnol 2022 40 11 1586 1600 10.1038/s41587-022-01491-z 36329321
Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol. 2022;40(11):1586–600.36329321 10.1038/s41587-022-01491-z
216. Zhang H Zhang L Lin A Xu C Li Z Liu K Liu B Ma X Zhao F Jiang H Algorithm for optimized mRNA design improves stability and immunogenicity Nature 2023 621 7978 396 403 10.1038/s41586-023-06127-z 37130545
Zhang H, Zhang L, Lin A, Xu C, Li Z, Liu K, Liu B, Ma X, Zhao F, Jiang H, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621(7978):396–403.37130545 10.1038/s41586-023-06127-z
217. Chehrazi-Raffle A Budde LE Pal SK Boosting CAR T cells with anti-tumor mRNA vaccines Nat Med 2023 29 11 2711 2712 10.1038/s41591-023-02623-x 37932550
Chehrazi-Raffle A, Budde LE, Pal SK. Boosting CAR T cells with anti-tumor mRNA vaccines. Nat Med. 2023;29(11):2711–2.37932550 10.1038/s41591-023-02623-x
218. Tang J Zeng C Cox TM Li C Son YM Cheon IS Wu Y Behl S Taylor JJ Chakaraborty R Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination Sci Immunol 2022 7 76 eadd4853 10.1126/sciimmunol.add4853 35857583
Tang J, Zeng C, Cox TM, Li C, Son YM, Cheon IS, Wu Y, Behl S, Taylor JJ, Chakaraborty R, et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol. 2022;7(76):eadd4853.35857583 10.1126/sciimmunol.add4853
219. Gote V Bolla PK Kommineni N Butreddy A Nukala PK Palakurthi SS Khan W A comprehensive review of mRNA vaccines Int J Mol Sci 2023 24 3 2700 10.3390/ijms24032700 36769023
Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, Khan W. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):2700.36769023 10.3390/ijms24032700
220. Uddin MN Roni MA Challenges of Storage and stability of mRNA-based COVID-19 vaccines Vaccines (Basel) 2021 9 9 1033 10.3390/vaccines9091033 34579270
Uddin MN, Roni MA. Challenges of Storage and stability of mRNA-based COVID-19 vaccines. Vaccines (Basel). 2021;9(9):1033.34579270 10.3390/vaccines9091033
221. Mulroney TE Pöyry T Yam-Puc JC Rust M Harvey RF Kalmar L Horner E Booth L Ferreira AP Stoneley M N(1)-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting Nature 2024 625 7993 189 194 10.1038/s41586-023-06800-3 38057663
Mulroney TE, Pöyry T, Yam-Puc JC, Rust M, Harvey RF, Kalmar L, Horner E, Booth L, Ferreira AP, Stoneley M, et al. N(1)-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature. 2024;625(7993):189–94.38057663 10.1038/s41586-023-06800-3
222. Ramachandran S Satapathy SR Dutta T Delivery Strategies for mRNA Vaccines Pharmaceut Med 2022 36 1 11 20 35094366
Ramachandran S, Satapathy SR, Dutta T. Delivery Strategies for mRNA Vaccines. Pharmaceut Med. 2022;36(1):11–20.35094366
223. Meyer MA Baer JM Knolhoff BL Nywening TM Panni RZ Su X Weilbaecher KN Hawkins WG Ma C Fields RC Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance Nat Commun 2018 9 1 1250 10.1038/s41467-018-03600-6 29593283
Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat Commun. 2018;9(1):1250.29593283 10.1038/s41467-018-03600-6
224. Lederer K Bettini E Parvathaneni K Painter MM Agarwal D Lundgreen KA Weirick M Muralidharan K Castaño D Goel RR Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals Cell 2022 185 6 1008 1024.e1015 10.1016/j.cell.2022.01.027 35202565
Lederer K, Bettini E, Parvathaneni K, Painter MM, Agarwal D, Lundgreen KA, Weirick M, Muralidharan K, Castaño D, Goel RR, et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022;185(6):1008–1024.e1015.35202565 10.1016/j.cell.2022.01.027
225. Kim SC Sekhon SS Shin WR Ahn G Cho BK Ahn JY Kim YH Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency Mol Cell Toxicol 2022 18 1 1 8 10.1007/s13273-021-00171-4 34567201
Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, Kim YH. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18(1):1–8.34567201 10.1007/s13273-021-00171-4
226. Corbett KS Edwards DK Leist SR Abiona OM Boyoglu-Barnum S Gillespie RA Himansu S Schäfer A Ziwawo CT DiPiazza AT SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Nature 2020 586 7830 567 571 10.1038/s41586-020-2622-0 32756549
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–71.32756549 10.1038/s41586-020-2622-0
227. Han X Xu J Xu Y Alameh MG Xue L Gong N El-Mayta R Palanki R Warzecha CC Zhao G In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors Nat Commun 2024 15 1 1762 10.1038/s41467-024-45537-z 38409275
Han X, Xu J, Xu Y, Alameh MG, Xue L, Gong N, El-Mayta R, Palanki R, Warzecha CC, Zhao G, et al. In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors. Nat Commun. 2024;15(1):1762.38409275 10.1038/s41467-024-45537-z
228. Huang X Kong N Zhang X Cao Y Langer R Tao W The landscape of mRNA nanomedicine Nat Med 2022 28 11 2273 2287 10.1038/s41591-022-02061-1 36357682
Huang X, Kong N, Zhang X, Cao Y, Langer R, Tao W. The landscape of mRNA nanomedicine. Nat Med. 2022;28(11):2273–87.36357682 10.1038/s41591-022-02061-1
229. Li X Qi J Wang J Hu W Zhou W Wang Y Li T Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape Theranostics 2024 14 2 738 760 10.7150/thno.84291 38169577
Li X, Qi J, Wang J, Hu W, Zhou W, Wang Y, Li T. Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape. Theranostics. 2024;14(2):738–60.38169577 10.7150/thno.84291
230. Miller CM Haimov M A simple rapid technique for vena cava clip replacement Surg Gynecol Obstet 1986 162 1 54 55 3510033
Miller CM, Haimov M. A simple rapid technique for vena cava clip replacement. Surg Gynecol Obstet. 1986;162(1):54–5.3510033
